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PRESENTACIÒN 
La replicación del ADN es un proceso que ha de ser controlado con precisión. Su 
desregulación genera un tipo de daño en el ADN conocido como estrés replicativo 
(ER). El ER se define como la acumulación de ADN de cadena sencilla (ssDNA) 
desprotegido en las horquillas de replicación (RF) que se han bloqueado. Debido a 
su naturaleza recombinogénica, el ssDNA puede causar reordenamientos 
genómicos, algunos de los cuales ocurren frecuentemente en cáncer. Una de las 
razones por las que se acumula ssDNA es un aporte insuficiente de nucleótidos 
(dNTPs) que limita la progresión de las ADN-polimerasas. De este modo, se ha 
propuesto que los niveles reducidos de dNTPs son una fuente de inestabilidad 
genómica en cáncer. Con objeto de proteger sus genomas, las células necesitan 
detectar y limitar la cantidad de ssDNA. ATR es la principal quinasa que responde a 
ER en mamíferos, lo que resulta en la activación de una cascada de fosforilaciones 
que limita el avance en el ciclo celular al tiempo que mantiene la integridad de las 
horquillas de replicación.  Si bien no se conoce el mecanismo exacto por el que la 
activación de ATR suprime ER, los resultados obtenidos en levadura sugieren que 
ATR podría estimular la producción de nucleótidos y así limitar el ER. En 
Saccharomyces cerevisiae, la mutación del ortólogo de ATR, Mec1, es letal y este 
fenotipo puede ser rescatado mediante la deleción simultánea de un inhibidor de la 
enzima ribonucleótido reductasa (RNR), Suppressor of Mec1 lethality 1 (Sml1). En 
todos los organismos eucariotas la RNR cataliza un paso limitante en la síntesis de 
dNTPs, reduciendo NDPs a dNDPs en un proceso que está altamente regulado. La 
RNR es un complejo heterotetramérico compuesto por una subunidad catalítica 
(Rnr1 o RRM1; en levadura o ratón, respectivamente) y una subunidad reguladora 
(Rnr2 o RRM2; en levadura o ratón, respectivamente), cuya estructura y función 
están muy conservadas a lo largo de la evolución. A pesar de que la secuencia que  
Sml1 reconoce en Rnr1 está conservada desde levaduras a mamíferos,  y a pesar de 
que Sml1 de levadura une e inhibe a la RNR de mamíferos in vitro, se desconoce si 
la regulación de la RNR por parte de ATR se conserva más allá de levaduras. 
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En este trabajo hemos investigado la posible relación entre ER, ATR y la actividad 
RNR, y hemos buscado nuevos reguladores de la RNR en mamíferos. Si bien no 
hemos conseguido identificar nuevos reguladores de la RNR, hemos establecido 
que un incremento de la actividad RNR alivia los fenotipos ocasionados por una 
deficiencia en ATR in vitro e in vivo, lo que indica que la regulación de los 
reservorios de dNTPs por parte de ATR está conservada en mamíferos. Además, 
hemos mostrado que la mutación de un sólo residuo conservado de RRM1 evita la 
interacción de esta proteína con RRM2, y causa letalidad embrionaria temprana en 
ratones. A pesar del impacto de esta mutación, los ratones Rrm1+/WG no presentan 
un fenotipo obvio, lo que sugiere que RRM1 está presente en exceso en células de 
mamífero. Estos datos revelan que la interacción entre RRM1 y RRM2 es esencial 
para la viabilidad celular, y proveen el primer modelo genético de pérdida de 
función de la RNR  en mamíferos. 
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ABSTRACT 
DNA replication is a tightly controlled process with its misregulation leading to a 
type of DNA damage, known as replication stress (RS). RS is essentially defined as 
an accumulation of unprotected single-stranded DNA (ssDNA) at stalled replication 
forks (RF). Due to the recombinogenic nature of ssDNA, it is a cause of genomic 
rearrangements frequently observed in cancer. One way by which ssDNA can arise 
is an insufficient supply of nucleotides (dNTPs), which limits the progression of the 
DNA polymerases. Accordingly, reduced dNTP levels have been proposed as a 
source of genomic instability in cancer. In order to protect their genomes, cells 
need to detect and limit the amount of ssDNA. ATR is the initial kinase that 
responds to RS in mammals, resulting in a phosphorylation cascade that finally 
leads to cell cycle arrest and safeguarding of replication fork integrity. While it 
remains unclear how exactly ATR suppresses RS, evidences from yeast suggest that 
ATR might reduce RS through stimulating the production of nucleotides. In 
Saccharomyces cerevisiae (S.cerevisiae), lethality of the ATR ortholog Mec1 can be 
rescued by concomitant deletion of Suppressor of Mec1 lethality1 (Sml1), an 
inhibitor of the ribonucleotide reductase (RNR). In all eukaryotes, RNR catalyzes a 
rate limiting step in dNTP synthesis by reducing NDPs to dNDPs in a tightly 
controlled process. The RNR is a heterotetrameric complex composed of a catalytic 
subunit (Rnr1 and RRM1 in yeast and mouse respectively) and a regulatory 
subunit (Rnr2 and RRM2 in yeast and mosue respectively) whose structure and 
function are well conserved throughout evolution. Although the sequence where 
Sml1 binds to Rnr1 is conserved in mammals and yeast Sml1 binds and inhibits the 
mammalian RNR, it remains unclear whether ATR-dependent regulation of RNR is 
conserved beyond yeast.  
In this work we investigated the putative relationship between RS, ATR and RNR 
activity, and searched for mammalian regulators of the RNR. Although we failed to 
identify new regulators of the RNR, we could establish that increased RNR activity 
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alleviates phenotypes associated with ATR-deficiency in mice in vitro and in vivo, 
pointing towards a functional conservation of the ATR-dependent regulation of the 
dNTP-pool in mammals. In addition, we show that a point mutation within a single 
conserved residue in RRM1 prevents binding to RRM2 causing early embryonic 
lethality in mice. Despite the impact of the mutation, Rrm1+/WG mice present no 
obvious phenotype suggesting that RRM1 exists in excess in mammalian cells. This 
data reveals that binding of RRM1 to RRM2 is essential for viability, and provides 
the first loss-of-function model of the RNR complex for genetic studies in 
mammals. 
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INTRODUCTION 
1 Nucleotide pools and genome integrity 
1.1 Replication Stress  
DNA is the vehicle that stores all the genetic information of a cell and this 
information needs to remain intact over generations. While maintenance of 
genomic integrity is essential for cell viability, loss or change of this information in 
the form of mutations is the driving force behind evolution. Nevertheless, 
mutations present a threat to genomic integrity. DNA is constantly exposed to 
mutagenic environmental agents such as ionizing radiation (IR), ultra violet (UV) 
radiation and reactive oxygen species (ROS). Additionally, a large part of DNA 
damage is caused by endogenous sources such as cellular metabolites (De Bont 
and van Larebeke, 2004) or the DNA replication process itself. Precisely 
orchestrated and complete DNA replication during every cell cycle is crucial and its 
misregulation leads to a type of DNA damage known as replication stress (RS). RS 
is defined as an accumulation of unprotected single-stranded DNA (ssDNA) at 
stalled replication forks (RFs). Unprotected ssDNA is prone to anneal with another 
strand, even an incorrect one if the RF keeps stalled. Moreover, stalled RFs are 
resolved through recombination, which generates double-strand breaks (DSBs) 
that threaten genome integrity. As a consequence, high levels of RS lead to 
mutagenesis and genome instability, a known cause of many human diseases such 
as cancer and premature ageing (Lecona and Fernandez-Capetillo, 2014; Zeman 
and Cimprich, 2014). Fork progression can be hindered by multiple causes such as 
difficult to replicate regions or by an insufficient supply of nucleotides (dNTPs) 
(Byun et al., 2005; Friedel et al., 2009; Paulsen and Cimprich, 2007; Tourriere and 
Pasero, 2007). The result of any of those conditions is the stalling of the RF while 
the replicative helicase (MCM2-7 complex) continues to unwind DNA, leading to an 
accumulation of persistent ssDNA (Byun et al., 2005; Nedelcheva et al., 2005; Sogo 
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et al., 2002). Due to the threat ssDNA poses to the cellular genome integrity, 
mechanisms have evolved to protect from and resolve RS structures, the so called 
RS response (RSR) (Harrison and Haber, 2006; Zhou and Elledge, 2000). Activation 
of the RSR is mediated through a phosphorylation cascade that signals to stabilize 
and restore RFs, control DNA damage response genes, repair pathway choices and 
cell cycle progression (Reviewed in (Lopez-Contreras and Fernandez-Capetillo, 
2010; Segurado and Tercero, 2009). The RSR is initially triggered by ssDNA, which 
becomes rapidly coated by the ssDNA-binding protein RPA. RPA-bound ssDNA 
brings ATRIP (ATR interacting protein), the constitutive binding partner of ATR, to 
the lesion (Cortez et al., 2001). In parallel, ssDNA-bound RPA also recruits the 
clamp loader RAD17 which in turn loads the Rad9-Rad1-Hus1 ring (9-1-1) onto the 
damaged site (Yang and Zou, 2006). Then, RAD17 recruits TopBP1 to activate ATR 
(Kumagai et al., 2006). In addition, RAD17 brings the adaptor protein Claspin to 
ssDNA, a step essential for the ATR-dependent phosphorylation of the effector 
kinase CHK1 (Wang et al., 2006). The DNA damage signal is extended to the rest of 
the nucleus via CHK1 signaling leading to stabilization and restart of the RF while 
arresting the cell cycle until the lesion is repaired (Cimprich and Cortez, 2008; 
Lopez-Contreras and Fernandez-Capetillo, 2010) (Figure 1). Of note, RS-free 
replication does not exist and as a consequence, ATR and CHK1 are essential for 
cell viability. In their absence, stalled forks that arise every S-phase cannot be 
stabilized and persist, causing a firing of backup origins which leads to a depletion 
of the dNTP pool, exacerbating RS and finally resulting in catastrophic fork 
collapse (Brown and Baltimore, 2000, 2003; Liu et al., 2000; Takai et al., 2000).  
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Figure 1: The ATR-mediated RS response maintains fork stability and orchestrates cell cycle 
progression. When progression of the RF is obstructed by a DNA lesions or a lack of dNTPs, the 
MCM2-7 complex may uncouple from the DNA-polymerases exposing long stretches of unprotected 
ssDNA (Byun et al 2005). This ssDNA is the activating signal for the RS response. RPA binds to the 
ssDNA, leading to binding of the ATR regulatory subunit ATRIP which in turn recruits ATR to the 
stalled fork. RPA is also the trigger for recruitment of Rad17 and a subsequent loading of the Rad-9 
Hus-1 Rad-1 clamp (9-1-1). Together, they signal to recruit and position TopBP1, the allosteric 
activator of ATR. ATR phosphorylates and activates its downstream kinase CHK1, which extends 
the RS signal throughout the nucleus leading to fork stabilization, inhibition of cell cycle 
progression, late origin firing and homologous recombination as well as an induction of RS-
response genes.  
1.2 A role for the RSR in the regulation of the dNTP pool 
Although ATR signaling has been an intense field of study, it remains mysterious 
how exactly it stabilizes stalled forks and limits RS. Proposed mechanisms include 
ATR-dependent regulation of the timely progression through the cell cycle (Liu et 
al., 2000), recombination-dependent restart of stalled RFs (Dehe et al., 2013) and 
regulation of replication factors (Lou et al., 2008). Data from yeast also suggest 
that ATR regulates dNTP pools to promote the coating of unprotected ssDNA (Zhao 
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et al., 2001; Zhao et al., 1998). In recent years, it has become increasingly clear that 
aberrant dNTP pools cause RS. In fact, some of the oldest anti-cancer drugs such as 
hydroxyurea (HU) and 5-fluorouracil induce RS though nucleotide pool depletion 
by targeting dNTP metabolic enzymes (Arlt et al., 2011; Gagou et al., 2010). Studies 
in yeast indicate that one of the essential roles of the ATR ortholog Mec1 is the 
induction of nucleotide production to reduce RS (Zhao et al., 2001; Zhao et al., 
1998). In S.cerevisiae, the lethality of the deletion of the ATR ortholog Mec1 can be 
rescued either by supplementation with nucleotides or by mutations that increase 
the activity or the levels of the key enzyme in dNTP production, the ribonucleotide 
reductase (RNR). For instance, viability of mec1Δ is rescued upon concomitant 
depletion of Crt1, the transcriptional repressor of the RNR subunits, or upon 
depletion of its allosteric inhibitor Sml1 (Huang et al., 1998; Zhao et al., 2001; Zhao 
et al., 1998). Transcriptional regulation of RNR genes by ATR through the Mec1-
Rad53-Dun1-RNR pathway is conserved to some extent in mammals through the 
ATR-CHK1-E2F1-RNR signaling (see Introduction 2.2.2), while no mammalian 
ortholog of Sml1 has been identified to date. However, recent studies provide 
proof that addition of nucleosides can alleviate RS in vertebrates (Bester et al., 
2011; Danilova et al., 2014). Nevertheless, to which degree ATR acts on the dNTP 
pool in mammals and whether this is one of its essential functions remains unclear.  
1.3 Alterations in the nucleotide pools cause genomic instability 
Optimal dNTP pools are critical for the fidelity of DNA replication and repair 
processes (Anglana et al., 2003) and their misregulation can lead to mutagenesis 
(Bester et al., 2011; Niida et al., 2010b). The control of dNTP pools is mainly 
achieved via allosteric and transcriptional regulation of enzymes involved in dNTP 
metabolism. Malfunctioning of those control mechanisms leads to altered dNTP 
pools resulting in enhanced mutagenesis, DNA recombination, chromosomal 
aberrations and cell death (Kunz et al., 1994). An excess of dNTPs primarily causes 
replication errors by driving misinsertions and promoting translesion DNA 
synthesis (Mathews, 2006), while dNTP scarcity slows down RF progression and 
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increases the frequency of fork stalling (Koc et al., 2004). dNTP levels also 
influence replication by affecting origin choice, inter-origin distance and dormant-
origin usage (Anglana et al., 2003; Courbet et al., 2008; Ge et al., 2007). Many 
oncogenes, such as Ras, Myc and cyclinE induce RS by forcing DNA hyper 
replication and excessive origin firing that results in the accumulation of partly 
replicated DNA and increased DNA damage (Di Micco et al., 2006; Dominguez-Sola 
et al., 2007; Jones et al., 2013). Recently, it was proposed that this so called 
oncogene-induced RS arises as a consequence of insufficient dNTP levels caused by 
an unscheduled activation of DNA replication (Bester et al., 2011). Normal cells 
react to low nucleotide levels (e.g. induced by HU treatment) by activating the RS 
checkpoint and reducing fork speed resulting in a prolongation of S-phase (Alvino 
et al., 2007; Koc et al., 2004), a mechanism that preserves the nucleotide pools and 
protects genome integrity (Bianchi et al., 1986; Koc et al., 2004; Matsumoto et al., 
1990). Many tumor cells have an inactive G1/S checkpoint and DNA synthesis is 
initiated in the presence of insufficient dNTPs causing excessive RS, increased DNA 
damage and accumulation of tumor promoting mutations (Sabatinos et al., 2012). 
While increased genomic instability due to mild levels of RS can enhance 
tumorigenesis, high levels of RS lead to unreplicated regions in the genome, 
hampering mitosis and resulting in mitotic catastrophe. Therefore, cancer cells are 
particularly dependent on a functional RS-response and increased levels of DNA 
precursors (Bester et al., 2011; Lecona and Fernandez-Capetillo, 2014). 
Accordingly, a mild increase in CHK1 levels protects cells from oncogene-induced 
RS and improves transformation efficacy (Lopez-Contreras et al., 2012). Similarly, 
changes in dNTP production through the alteration of key metabolic enzymes is a 
recurring feature in onco- and tumor-suppressor genes respectively (Aird and 
Zhang, 2015; Angus et al., 2002; Aye et al., 2015). High dNTP levels are mutagenic, 
but in contrast to low dNTP levels, compatible with survival. In yeast, upregulation 
of RNR activity seems to be a general response to RS (Davidson et al., 2012) and 
mutants with increased dNTP pools show improved survival following DNA 
damage while exhibiting higher mutation rates (Chabes et al., 2003a). In mammals, 
rate-limiting enzymes for dNTP production such as RNR and thymidylate synthase 
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(TS) are under the direct control of the E2F and Myc oncogenes and are commonly 
upregulated in human cancers (Aye et al., 2015). In addition, RNR activity has been 
proposed to play a role in overcoming oncogene-induced senescence in neoplastic 
cells (Aird and Zhang, 2015; Mannava et al., 2012; Mannava et al., 2013). The 
retinoblastoma tumor suppressor RB on the other hand, reduces expression of 
dehydrofolate reductase, RNR and TS (Angus et al., 2002). Hence, appropriate 
dNTP levels are required for normal cell proliferation and repair and excessive 
dNTP levels become essential after malignant transformation to sustain cancer 
progression.  
2 Nucleotide biosynthesis 
Nucleotides are composed of a nitrogenous base coupled to a five-carbon sugar 
(ribose or deoxyribose) (nucleoside) and one to three phosphate groups 
(nucleotide mono-, di-, tri-phosphate). Nucleotides have various functions 
essential for cell viability acting as an energy source (ATP, GTP and CTP), as part of 
coenzymes (AMP in NAD or Coenzyme A), as structural components of 
phospholipids or, and most prominently, as building blocks of DNA and RNA. In 
mammals, nucleotides can be newly synthesized through the de novo dNTP 
production pathway (DNP) or reused in the nucleoside salvage pathway (NSP).   
2.1 De novo dNTP production  
In the de novo pathway, both purines (Adenosine, Guanosine) and pyrimidines 
(Cytidine, Uridine, Thymidine) are synthesized from 5’-phospho α-D-ribosyl-1-
pyrophosphate (PRPP) and amino acids (Mathews, 2006). Purine production 
involves the synthesis of inosine monophosphate (IMP) that is then converted via a 
separate two-step process into either AMP or GMP, which are subsequently 
phosphorylated to the corresponding NDP or NTP via specific kinases. Pyrimidine 
synthesis begins with the generation of the nitrogenous base orotate as free bases 
starting from orotic acid that is converted to its nucleotide OMP. OMP 
decarboxylation yields UMP that becomes subsequently phosphorylated to UTP. 
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Addition of glutamine to UTP generates CTP while dTMP is formed from dUMP 
(Figure 2).  
  
Figure 2: Purine and pyrimidine de novo dNTP synthesis in mammalian cells. Each enzyme 
name is in gray italics (Modified from (Mathews, 2006)). 
2.2 Ribonucleotide reductase  
RNR catalyzes the rate-limiting step in de novo dNTP synthesis (Figure 2) and the 
first step specifically dedicated to DNA synthesis by reducing all four types of NDPs 
to dNDPs (Figure 3) in a tightly controlled process. In fact, and although dNTP 
production is a multistep process including many different enzymes (see Figure 
2), the balance of the dNTP pool is primarily determined by the regulatory 
mechanisms of the RNR (Mathews, 2006).  
Introduction 
[27] 
 
 
Figure 3: Ribonucleotide reductase (RNR) catalyzes the rate limiting step in de novo 
synthesis of dNTPs. Catalysis of ribonucleoside 5’-diphosphate (NDP) involves the reduction of the 
hydroxyl group at the 2’-carbon of ribose 5-phosphate to form the 2’-deoxy derivative-reduced 2’-
deoxyribonucleoside 5‘-diphosphate (dNDP). 
There are three classes of RNR enzymes, distinguished by their catalytic 
mechanism. Eukaryotes (and some prokaryotes like Escherichia coli and viruses) 
contain Class-I RNRs, a heterotetrameric complex composed of two non-identical 
dimeric subunits. The minimal catalytically active RNR is an α2β2 complex (Fu et 
al., 2013; Minnihan et al., 2013; Uhlin and Eklund, 1994), although the α6β2 form 
has been proposed as the predominant form under physiologic conditions 
(Rofougaran et al., 2006). The α and β subunits are encoded by the R1 and R2 
genes, respectively. The large subunit R1 (Rnr1 and RRM1 in yeast and mouse 
respectively) contains the catalytic site for reduction of the nucleotide as well as 
two allosteric sites for its regulation. The small subunit R2 (Rnr2 and RRM2 in 
yeast and mouse) carries a non-heme iron center (Fe-O-Fe) for the oxygen-
dependent generation of a stable tyrosyl radical necessary for the reduction step.  
While each R2 monomer carries the di-iron center, only one tyrosyl radical is 
formed during each reduction cycle (Cotruvo and Stubbe, 2011). During catalysis, 
the radical is continuously shuttled via a long range proton-coupled electron 
transport chain to redox-active cysteines in the R1 active site to generate the thiyl 
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radical that reduces NDPs (Minnihan et al., 2013; Nordlund and Reichard, 2006).  
The active site, oxidized and inactive after this step, becomes subsequently 
activated by re-reduction of the cysteines via interaction with the R1 C-terminal 
domain (CTD) of the neighboring R1 subunit, preparing it for a new cycle of 
catalysis (Zhang et al., 2007). 
2.2.1 Allosteric regulation of the RNR 
The complex mechanism of allosteric regulation of the RNR was discovered long 
ago by Brown and Reichard (Brown and Reichard, 1969). The RNR contains two 
allosteric sites, both located in the R1 subunit. Overall enzyme activity is controlled 
by the activity site (a-site), while substrate choice is determined by the specificity 
site (s-site). The a-site is an ATP cone domain located in the N-terminus of the R1 
subunit (Aravind et al., 2000). It is activated by ATP and inhibited by dATP binding, 
turning off nucleotide production whenever dNTP levels rise above a certain 
threshold (Nordlund and Reichard, 2006). The importance of the a-site specific 
regulation is exemplified by a mutation in the a-site that abolishes dATP feedback 
inhibition in yeast. This mutation leads to a 3-fold increase in the pyrimidine and a 
9-fold increase in the purine dNTP pool accompanied by a 100 fold increased 
mutation rate (Weinberg et al., 1981). The s-site binds ATP, dATP, dTTP and dGTP; 
ATP and dATP binding favors the reduction of CDP and UDP, whereas dTTP and 
dGTP stimulate GDP and ADP reduction, respectively. The s-site is located at the 
R1-dimer interface and acts as a sensor to detect the concentration of each dNTP. 
Binding of each allosteric effector to the s-site induces a conformational change in 
a flexible loop, transmitting the specific signal to the catalytic site and thus making 
it more amenable for the corresponding substrate (Figure 4). The interaction 
between the s-site and its allosteric effectors has been proposed to induce the 
dimerization of the R1 subunits and the subsequent RNR heterocomplex assembly 
(Rofougaran et al., 2006). The s-site specific regulation is important as the 
physiological equilibrium of dNTP levels may vary between organisms, but its 
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accuracy is crucial for genome integrity (Hofer et al., 2012; Nordlund and Reichard, 
2006).  
 
Figure 4: Schematic view of the RNR holoenzyme.  The RNR heterotetramer is formed by two 
large R1 subunits and two small R2 subunits. R1 contains the active site for NDP reduction and two 
allosteric sites that regulate overall enzyme activity (activity site) and substrate specificity 
(specificity site). RNR is active when ATP is bound to the a-site and interaction of ATP, dATP, dGTP 
or dTTP with the s-site induce reduction of the according nucleotide. The R2 subunit contains a di-
ferric iron center (Fe-Fe) and one subunit forms the protein tyrosyl radical(Y-O+) that is transferred 
to the R1 subunit for catalysis.  
2.2.2 RNR transcriptional and post-transcriptional regulation 
Aside from its sophisticated allosteric control mechanism, multiple levels of RNR 
regulation exist. They function in concert to strictly limit RNR activity to those 
stages of the cell cycle when the requirement for dNTPs is highest, namely S/G2-
phase and during DNA damage repair. As a consequence, RNR protein levels and 
activity start to rise at the G1/S border, resulting in a ten-fold increase in dNTP 
levels, which decrease before cells enter into mitosis (Mathews, 2006). The cell 
cycle restricted activity of RNR is observed from yeast to human and achieved via 
conserved as well as distinct regulatory mechanisms, including: transcription, 
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protein inhibitor interaction, protein degradation and control of subcellular 
localization.  
RNR transcriptional regulation in yeast 
In budding yeast (S.cerevisiae), the R1 dimer is formed by the products of two 
genes, rnr1 and rnr3. Only rnr1 is essential for viability forming the Rnr1 
homodimer under standard conditions, while Rnr3 is normally present at low 
levels. In response to DNA damage or replication block, Mec1 is activated and 
phosphorylates Rad53. Rad53, in turn, phosphorylates the Dun1 kinase that acts 
on Crt1, a transcriptional repressor of different rnr genes as well as of its own 
promoter. Crt1 phosphorylation induces its release from DNA, leading to 
transcriptional activation of its target genes (Lubelsky et al., 2005). As a 
consequence, rnr3 is induced and accumulates in the cytoplasm, allowing the 
formation of an alternative R1 dimer (Mathews, 2006; Wu and Huang, 2008). In 
contrast, transcription of rnr1 is regulated by the dimeric MluI-binding factor 
(MBF) composed of the regulatory transactivating protein Swi6 and its DNA 
binding partner Mbp1 (Reviewed in (de Bruin and Wittenberg, 2009)). In addition, 
rnr1 expression is controlled during the cell cycle and in response to DNA damage 
by the high-mobility group transcription factor Ixr1 (Tsaponina et al., 2011). In 
budding yeast, the R2 subunit is a constitutive heterodimer formed by the 
products of two essential genes, rnr2 and rnr4 (Huang and Elledge, 1997; Perlstein 
et al., 2005; Sommerhalter et al., 2004). Only Rnr2 is able to form the diferric 
tyrosyl cofactor while Rnr4 lost this ability but is essential for radical generation 
and stabilization of the heterodimer (Chabes et al., 2000; Perlstein et al., 2005; 
Voegtli et al., 2001). Like rnr3, rnr2 and rnr4 are under the control of the Crt1 
repressor and induced in response to DNA damage response (DDR) signaling 
(Huang et al., 1998; Zhao and Rothstein, 2002) (Figure 5).  
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Figure 5: Transcriptional regulation of RNR in S.cerevisiae. Mec1 signaling induces a 
phosphorylation cascade that activates the downstream kinases Rad53 and Dun1 which finally 
leads to a transcriptional de-repression of the rnr genes rnr2-4.  Expression of rnr1 depends on 
Mec1 and Rad53 but not on Dun1 and is instead regulated through Ixr1 and the Mec1-independent 
MBF heterocomplex (Modified from (Sanvisens et al., 2013)). 
RNR post-transcriptional regulation in yeast 
In budding yeast, an additional level of RNR regulation is achieved through the 
interaction with a small allosteric inhibitor, the Sml1 protein (Chabes et al., 1999; 
Zhao et al., 1998). Sml1 specifically binds to the large R1 subunit, inhibiting dNTP 
production whenever DNA synthesis is not desired (Chabes et al., 1999). Upon 
entry into S-phase or in response to DNA damage, Mec1 signaling activates the 
downstream kinase Dun1, which in turn phosphorylates Sml1. Phosphorylated 
Sml1 becomes ubiquitinated by the E2/E3 ubiquitin ligase complex Rad6-Hbr2-
Hub1, resulting in its proteasomal degradation. Zhang and colleagues propose a 
model where Sml1 competes with the R1-CTD for the interaction with the N-
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terminal domain (NTD) of the neighboring R1, blocking an essential step for 
complex regeneration (Zhang et al., 2007) (Figure 6).  
 
Figure 6: A model for the inhibition of Rnr1 by Sml1. The active site becomes oxidized and 
inactive after each catalytic cycle. Interaction of the C-terminal domain (CTD) of the neighboring R1 
with a conserved region in the R1-N-terminal domain (NTD) is essential for re-reduction and re-
activation of the RNR. Sml1 competes against R1-CTD for the binding to this region in the R1-NTD, 
blocking regeneration of the complex (Modified from (Zhang et al., 2007). 
Under unperturbed conditions, Sml1 is present as a free homodimer and in 
equilibrium with the inactive Sml1-Rnr1 complex. Upon Mec1 initiated 
degradation of free Sml1, the equilibrium shifts towards an active RNR that can 
now produce dNTPs for DNA replication or repair (Zhao et al., 2001; Zhao and 
Rothstein, 2002). The removal of the RNR inhibitor provides a much faster 
mechanism to induce dNTP production compared to transcriptional regulation and 
its significance is underlined by the fact that deletion of Sml1 rescues the lethality 
of mec1∆ strains (Zhao et al., 1998).  
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RNR localization in yeast 
In both fission and budding yeast, the R2 subunit localizes predominantly to the 
nucleus outside of S-phase and relocalizes to the cytoplasm in response to S-phase 
entry or DNA damage checkpoint activation (Liu et al., 2003). Since R1 
constitutively localizes to the cytoplasm, R2 relocalization is a prerequisite for RNR 
complex formation and dNTP production (Nestoras et al., 2010). In S.cerevisiae, 
Dif1 (Damage regulated import factor 1) regulates Rnr2-nuclear import (Lee et al., 
2008; Wu and Huang, 2008) while nuclear sequestration of Rnr2 is achieved 
through binding to the WD40 repeat protein Wtm1 (Lee and Elledge, 2006). In 
response to S-phase entry or DNA damage, Dif1 becomes phosphorylated and 
degraded in parallel. The Wtm1-Rnr2 interaction is weakened while nuclear 
export remains active leading to a cytoplasmic accumulation of Rnr2 with 
subsequent RNR complex formation and activation (Lee et al., 2008; Wu and 
Huang, 2008) (Figure 7). Dif1 and Sml1 are related genes and share a common 
domain, the Sml1 domain, involved in phosphorylation-dependent degradation 
(Lee et al., 2008; Wu and Huang, 2008). In addition, the S.cerevisiae RNR regulatory 
gene cluster contains a third gene, Hug1. Hug1 shares with Dif1 a sequence motif 
that is involved in binding to R2 (Lee et al., 2008; Nestoras et al., 2010) and that 
was suggested to fine-tune RNR activity (Meurisse et al., 2014). In S.pombe, Spd1 
regulates both R2 nuclear import as well as inhibition of R1 (Hakansson et al., 
2006a). Spd1 shows limited sequence homology to Dif1/Sml1/Hug1 in different 
functional regions (Lee et al., 2008): the proposed R1 interaction domain shows 
similarity to the Rnr1 binding domain of Sml1 (Nestoras et al., 2010; Zhao et al., 
2000) and the R2-interaction domain presents homology to the corresponding 
region in Dif1/Hug1 (Lee et al., 2008; Nestoras et al., 2010). It has been proposed 
that gene duplication events of the ancestral RNR-regulatory locus led to a 
separation into three distinct genes in S.cerevisiae (Meurisse et al., 2014). The 
coordinated regulation of RNR activity allows a two-fold increase in the dNTP pool 
during replication or a 6-8 fold increase after the activation of the DDR, ensuring 
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efficient DNA replication and repair while preventing large dNTP pool expansions 
that might induce genotoxicity (Chabes and Thelander, 2003).  
 
Figure 7: Post-transcriptional regulation of the RNR in S.cerevisiae.  During S-phase and in 
response to genotoxic stress, Mec1 signaling phosphorylates and activates its downstream kinases 
Rad53 and Dun1 which leads to activation of RNR by (1) promoting the phosphorylation and 
degradation of the Rnr1-inhibitor Sml1 and (2) inducing Rnr2 cytosolic accumulation by 
degradation of its nuclear importer Dif1 and weakening the interaction of Rnr2 with Wtm1.  
RNR transcriptional regulation in mammals 
The mammalian RNR complex is a heterotetramer formed by two identical RRM1 
subunits and two RRM2 subunits. Mammals contain an additional R2 gene, p53R2, 
which codes for a protein called RRM2B. p53R2 was discovered in 2000 by two 
groups (Nakano et al., 2000; Tanaka et al., 2000) and shares about 80%-90% 
sequence homology and domain conservation with RRM2. RRM2B can form a 
functional complex with RRM1 and provides dNTPs for mitochondrial replication 
and DNA repair outside of S-phase (Lozano and Elledge, 2000; Nakano et al., 2000; 
Tanaka et al., 2000). The discovery of p53R2 directly connected DDR signaling to 
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RNR activity in higher eukaryotes since p53R2 is induced in response to p53 
signaling and ATM phosphorylates and stabilizes RRM2B (Chang et al., 2008).  
Transcription of Rrm1 and Rrm2 is cell cycle-dependent, with undetectable mRNA 
levels in G0/G1 phase and levels peaking in S-phase (Bjorklund et al., 1990). The 
Rrm1 promoter presents an Inr element and 3 control regions (β, α, and γ). 
Promoter strength is sustained by binding of the YY1 transcription factor to β and 
α regions while cell cycle-dependent regulation contributes to enhance promoter 
activity (Johansson et al., 1998). Rrm2 contains a TATA-box within its core 
promoter region, an upstream promoter activating region crucial for overall 
activity, a proximal promoter binding element containing an E2F4 binding site and 
an adjacent NF-Y binding CCAAT motif (Filatov and Thelander, 1995). During G1, 
E2F4 binds to the conserved E2FII binding site, leading to repression of 
transcription. Upon entry into S-phase, E2F4 dissociates and relieves Rrm2 
repression leading to transcriptional activation (Chabes et al., 2004). Analog to the 
Mec1-Rad53-Dun1-dependent regulation of RNR genes in yeast, mammalian RNR 
genes seem to be under the control of ATR/ATM-CHK1-E2F signaling (Eaton et al., 
2007; Zhang et al., 2009). Several studies report either no induction of Rrm2 
expression after DNA damage (Chabes and Thelander, 2000) or even inhibition by 
p53 (Lin et al., 2004; Tanaka et al., 2000; Yamaguchi et al., 2001). In contrast,  
others claim that Rrm2 is induced in response to some DNA insults (UV light) but 
not to others (HU) (Filatov et al., 1996). However, the induction of Rrm1 and p53R2 
expression in response to DNA damage is well established (Eaton et al., 2007; 
Nakano et al., 2000; Tanaka et al., 2000), and an increasing number of studies also 
report that Rrm2 is indeed upregulated in response to DDR signaling. In this sense, 
the Crt1 mediated repression of RNR genes is functionally conserved in mammals. 
The mammalian ortholog of Crt1, Rfx1, binds and represses the Rrm2 gene as well 
as its own promoter in unperturbed conditions, but is released upon CHK1 
signaling resulting in de-repression of its target genes (Lubelsky et al., 2005).  In 
contrast to Rrm2, the p53R2 gene is not cell cycle regulated but expressed at low 
levels throughout the cell cycle and highly induced in response to p53 signaling 
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(Nakano et al., 2000; Tanaka et al., 2000). In the absence of p53, p53R2 is not 
induced. Instead, RRM2 levels increase to provide dNTPs for repair (Lin et al., 
2004). Of note, efficient induction of p53R2 expression takes roughly 24 hours 
leading to a less than 2-fold increase in the dNTP pool in G0/G1 (Hakansson et al., 
2006b). DNA damage repair is thought to take place within hours after damage 
(Smith and Seo, 2002) indicating that other factors such as RNR localization or 
activation must provide sufficient dNTPs for DNA replication and repair.  
RNR post-transcriptional regulation in mammals 
Compared to yeast, mammals exhibit a more stringent allosteric regulation of the 
activity of RNR, and can further regulate dNTP pools via the salvage pathway (see 
Introduction 2.3) and a dNTP secretion system, pathways absent in yeast. Much 
less is known about post-transcriptional regulatory mechanisms of RNR activity in 
mammals and some of them remain controversial. Nevertheless, it is clear that 
mammalian cells also regulate the RNR at the post-transcriptional level. In contrast 
to yeast, overall activity of mammalian RNR is controlled through the modulation 
of the levels of the small subunit RRM2. Although expression of both, Rrm1 and 
Rrm2 is regulated in a cell cycle-dependent manner, the regulation of their protein 
levels differs greatly. RRM1 protein has a very long half life (>20 hours) resulting 
in almost constant levels that are thought to be in excess throughout the cell cycle 
(Engstrom et al., 1985). In contrast, RRM2 has a short half life (3 hours) and is only 
stable during S-phase and in response to DNA damage signaling. During G0/G1 and 
in late mitosis, RRM2 becomes ubiquitinated and degraded by the anaphase 
promoting complex (APC) (Chabes and Thelander, 2000; Chabes et al., 2003b). 
RRM2B lacks the KEN box, the sequence recognition motif for the APC present in 
the RRM2 sequence, and hence is not degraded. Recently, a study by D’Angiolella 
(D'Angiolella et al., 2012) reported an additional mechanism of RRM2 protein 
regulation via SCFCyclinF-dependent degradation during G2. This study linked 
ATR signaling to RNR activity showing that ATR signaling decreases CyclinF levels, 
leading to a stabilization of RRM2 in G2 (D'Angiolella et al., 2012).  
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Regarding the allosteric inhibition of the mammalian RNR, two recent studies 
reported the interaction and inhibition of mammalian RNR by different proteins. 
Xie and colleagues found that the anti-apoptotic protein Bcl2 binds RRM2 and 
inhibits RNR complex formation causing reduced RNR activity, dNTP levels and RS 
(Xie et al., 2014). In a different study, a protein involved in ion-transport, IRBIT, 
was found to bind and inhibit the RNR, but this interaction was limited to the 
RRM1-RRM2B complex and could only be observed during mitosis (Arnaoutov and 
Dasso, 2014). While these studies propose the existence of new inhibitors of the 
mammalian RNR, their impact on RNR function during replication and whether 
and how they are linked to ATR signaling remains unknown. 
RNR localization in mammals 
Another unresolved question is whether RNR activity is controlled via subcellular 
localization of the complex in mammals (Pontarin et al., 2008). The bulk of RRM1 
and RRM2 protein localizes to the cytoplasm. Hence, it is generally believed that 
nucleotide synthesis takes place in the cytosol and newly synthesized dNTPs enter 
the nucleus by diffusion (Engstrom and Rozell, 1988; Pontarin et al., 2008). 
However, several works have suggested that nucleotides could be synthesized in 
close proximity to RFs. For instance, Reddy and Pardee proposed nuclear 
translocation of the RNR (Prem veer Reddy and Pardee, 1980). In addition, 
Mathews and others found that the cellular concentration of dNTPs is about four 
times lower than that required for DNA synthesis (Mathews and Sinha, 1982; 
Warner, 1973) and speculated that the RNR might form part of the so called 
replisome. In this model the RNR and other dNTP synthesizing enzymes are 
associated to the replication machinery to provide a locally increased supply of 
DNA precursors at the site of synthesis. Studies in E.coli corroborate this 
hypothesis, as the R1 subunit co-localizes with replication factors (Sanchez-
Romero et al., 2010). It is becoming increasingly clear that at least small fractions 
of the RNR subunits translocate to the nucleus to promote DNA damage repair. 
CHK1 signaling not only regulates RRM2 transcription but also induces RRM2 
nuclear translocation (Zhang et al., 2009) and RRM2 and RRM2B were found to 
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enter the nucleus in human tumor cell lines (Liu et al., 2005). In 2010, Niida and 
colleagues showed that a small fraction of RRM1 and RRM2 associates with 
chromatin in a Tip60-dependent manner and are localized to sites of DSB (Niida et 
al., 2010a). Recently, Hu and colleagues demonstrated that the association of the 
thymidylate kinase (TMPK) and RNR to DNA lesions is required for DSB repair (Hu 
et al., 2012). Finally, D’Angiolella et al provided evidence of a nuclear accumulation 
of RRM2 dependent on ATR-induced stabilization of RRM2 during G2 (D'Angiolella 
et al., 2012). While the nuclear translocation of the RNR in response to DNA repair 
is now well established, it remains unclear whether the RNR also localizes to sites 
of DNA replication and RS. 
2.3 The nucleotide salvage pathway 
Apart from the DNP for dNTP synthesis, mammalian cells feature an additional 
RNR-independent pathway to generate nucleotides, the nucleotide salvage 
pathway (NSP). While actively replicating cells mainly rely on the DNP for 
nucleotide production, the NSP is the main source of dNTPs in quiescent cells (Kufe 
et al., 1984; Sandoval et al., 1996). The NSP recycles extracellular 
deoxyribonucleosides from nucleic acid degradation (DNA turnover and food 
intake) and apoptotic cells (Arner and Eriksson, 1995). The precursors are 
imported via specialized transporters and phosphorylation by specific kinases 
generates the final nucleotide (Reichard, 1988). Deoxycitidine kinase (dCK) 
phosphorylates deoxycitidine and, to a lesser extent, deoxyadenosine and 
deoxyguanosine, while thymidine kinase 1 (TK1) phosphorylates thymidine 
(Reichard, 1988). The NSP was long considered irrelevant for the regulation of 
dNTP pools (Xu et al., 1995) but, more recently, studies indicate that it might affect 
DNA replication and repair under certain conditions. Depletion of dCTP pools in 
dCK-/- mice leads to RS, S-phase arrest and DNA damage in hematopoietic 
progenitor cells, which can be rescued by concomitant depletion of TK1 (Austin et 
al., 2012; Toy et al., 2010). Although the bulk of NSP-derived free dNTPs does not 
contribute to DNA synthesis under unchallenged conditions (Nathanson et al., 
Introduction 
[39] 
 
2014), dNTP synthesis via the NSP becomes critical for the maintenance of 
nucleotide levels when de novo dNTPs synthesis is inhibited (Austin et al., 2012). 
Moreover, dCK is a target of ATM and ATR kinases (Matsuoka et al., 2007), 
supporting that induction of the NSP pathway might be important to produce 
sufficient dNTPs in response to DNA damage and RS. The induction of an 
alternative dNTP production mechanism might also explain resistance towards the 
cytotoxic effects of drugs targeting dNTP de novo synthesis such as thymidine, 
which inhibits RNR-dependent pyrimidine synthesis (Reichard, 1988). 
Interestingly, a recent study showed that the combination of thymidine and dCK 
inhibitors can be efficient in treatment of hematological malignancies in mice 
(Nathanson et al., 2014). Therefore, concomitant targeting of DNP and NSP could 
provide an effective alternative to target cancer cells and reduce the development 
of resistances to treatment.  
3 RNR in cancer and disease 
As the key regulator of dNTP de novo biosynthesis, RNR plays a pivotal role in 
maintaining genome integrity. Altered regulation of its activity is highly mutagenic 
(Chabes et al., 2003a; Mathews, 2006) and its upregulation has been described in 
certain types of human cancer (Elford et al., 1970). However, the RNR subunits 
seem to play distinct roles in tumor development. RRM2, being considered the 
rate-limiting subunit of RNR, is overexpressed in a number of human cancers 
including gastric, ovarian, bladder and colorectal cancer (Lu et al., 2012; Morikawa 
et al., 2010; Wang et al., 2012). A clear oncogenic activity for RRM2 was described 
in human carcinoma cells in vitro, where high RRM2 expression enhanced invasive 
potential (Duxbury et al., 2004b) and in mouse, where increased focus formation 
and anchorage independent growth was enhanced by RRM2 overexpression (Fan 
et al., 1998; Fan et al., 1996).  
Similarly, suppression of the alternative small subunit RRM2B inhibits cancer cell 
proliferation (Matsushita et al., 2012) and increased expression of p53R2 is 
detected in melanoma, oral carcinoma, esophageal squamous cell carcinoma and 
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non-small cell lung cancer (NSCLC) (Matsushita et al., 2012; Okumura et al., 2006; 
Uramoto et al., 2006; Yanamoto et al., 2009; Yanamoto et al., 2003). In other 
cancers, such as colon adenocarcinoma and colorectal cancer, p53R2 expression is 
negatively correlated with metastasis formation (Liu et al., 2006), cell invasiveness 
and survival (Liu et al., 2011).  
In contrast to the small subunits, a tumor suppressive function has been proposed 
for the large RRM1 subunit and its overexpression reduces transformation in vitro 
(Fan et al., 1997). The RRM1 locus shows frequent loss of heterozygosity in lung 
cancers and high levels of RRM1 expression are associated with increased survival 
rates. Mouse models overexpressing RRM1 confirmed the tumor suppressor 
activity of RRM1 which seems to be mediated by improved DNA damage repair 
(Gautam and Bepler, 2006). However, it has been speculated that the tumor 
suppressive function might not be solely related to RRM1’s function in dNTP 
production, as migration and invasion, tumorigenicity and metastasis are mediated 
via RRM1-dependent induction of PTEN (Gautam et al., 2003).  
3.1 Targeting dNTP metabolism for cancer treatment 
Owing to the increased proliferation rates and genomic instability of transformed 
cells, tumor cells are more sensitive to the cytotoxic effects of dNTP deprivation. 
Thus, RNR and other dNTP metabolic enzymes are major targets in several types of 
cancer treatments (Aye et al., 2015; Bonate et al., 2006; Zhu et al., 2009). In fact, 
the first chemotherapy ever developed was an antifolate, a compound which 
essentially limits dNTP production. Folates are B9 vitamins that serve as co-factors 
in multiple crucial biosynthetic pathways including de novo biosynthesis of purines 
and thymidylate and, as such, are essential for cell division, DNA synthesis and 
repair. Most antifolates inhibit the dihydrofolate reductase (DHFR), antagonizing 
the function of folic acid. In the 1940s, Sidney Farber discovered that antifolates 
can inhibit the proliferation of malignant cells and showed some effectiveness in 
the treatment of acute lymphoblastic leukemia (Farber and Diamond, 1948). 
Nowadays, a large number of newly designed antifolates are still in clinical use (e.g. 
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Methotrexate) (Walling, 2006) and various other antimetabolites such as 
nucleoside analogs have been developed for the treatment of cancer and other 
diseases.  
Many nucleoside analogs inhibit the RNR subunit RRM1 by blocking either its 
active or allosteric sites (Reviewed in (Shao et al., 2013)). For instance, 
Gemcitabine (dFdC), a cytidine analog, is used in the clinic for the therapy against 
pancreatic, bladder and lung cancer (Reviewed in (Stubbe and van der Donk, 
1995). As most nucleoside analogs, it is administered as a prodrug that needs to be 
phosphorylated in order to be active (Bonate et al., 2006). In the case of 
Gemcitabine, the diphosphate analog binds and inhibits the RRM1 active site 
irreversibly while the triphosphate can be incorporated into DNA leading to 
termination of chain elongation. The reduced dNTP levels caused by RRM1 
inhibition lead to increased incorporation of the dNTP analog into the DNA 
potentiating its effect (Artin et al., 2009; Plunkett et al., 1995). Despite the success 
of nucleoside analogs in the clinic, they also feature some disadvantages (Alvarez-
Salas, 2008). Overexpression of the target enzyme can result in resistance to the 
drug (Goan et al., 1999) and metabolism or catabolism of the prodrug and 
nucleos(t)ide analogs respectively can lead to dangerous side effects and toxicity 
(Gonzalez et al., 1998; King et al., 2006; Lindemalm et al., 2004). Because inhibition 
of the RNR can induce sensitivity to DNA damage-inducing agents, nucleoside 
analogs such as Gemcitabine are commonly used in combination therapy. For 
instance, in Carboplatin-resistant tumors a combination of Gemcitabine with 
Carboplatin (Pfisterer et al., 2005) has proven efficient to overcome resistances 
(Sandler and Ettinger, 1999). 
In addition, RNR can be inhibited via targeting of the RRM2 subunit. Most RRM2 
inhibitors are metal chelators and/or radical quencher affecting the tyrosyl radical 
or the iron center. HU inactivates RNR by targeting both, the tyrosyl radical and the 
iron center. It was first synthesized in 1869 and primarily used for 
myeloproliferative disorders which can develop into acute myeloid leukemia and 
for which it is still used in the clinic (Sterkers et al., 1998). HU is also used for the 
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treatment of chronic myelogenous leukemia (Hehlmann et al., 2011), glioblastoma 
(Levin, 1992) and in combination with radiotherapy in cervical and head and neck 
cancer. However, cancer cells frequently develop resistance by overexpressing 
RRM2 (Akerblom et al., 1981; McClarty et al., 1987; Wright et al., 1987). In 
addition, HU has a short half-life, low affinity for RNR and may target other 
metalloenzymes (Temperini et al., 2006). The iron chelator Triapine is a more 
potent inhibitor of RNR than HU and has shown promising results in clinical trials 
for combination treatment with cisplatin/radiation in human cervical and vaginal 
cancer (Kunos et al., 2010; Kunos et al., 2013). Triapine has also shown to be 
effective against HU-resistant tumors (Finch et al., 2000). Besides small molecule 
inhibitors, new targeting strategies are currently being investigated including RNR 
gene silencing approaches. Although this strategy is still limited by technical 
obstacles, such as inefficient siRNA-delivery in patients (Oh and Park, 2009), early 
clinical trials show promising results (Cao et al., 2003; Duxbury et al., 2004a; 
Rahman et al., 2012). Further improvements of the techniques, new combination 
therapiess and deeper understanding of the regulatory pathways controlling dNTP 
levels are likely to help improve cancer therapy in the future. 
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In summary, the adequate regulation of nucleotide levels by RNR is necessary for 
genomic integrity and its misregulation has emerged as an important source for RS 
in tumor development.  How the RS checkpoint (ATR and CHK1) suppresses RS 
and whether this is at any level linked to dNTP biosynthesis is not known. 
However, evidences from yeast suggest that the essential function of the ATR 
ortholog Mec1 is indeed linked to the regulation of the dNTP pool. Whereas the 
structure and function of RNR are highly conserved during evolution, it remains 
unclear to what extent the ATR-dependent regulation of the RNR is conserved in 
mammals. Based on the above, we hypothesized that the essential roles of 
mammalian ATR might also relate to dNTP production. Verifying this putative 
relationship between ATR and RNR, and the search for mammalian regulators of 
RNR activity constitute the main objectives of my PhD. 
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OBJECTIVES 
1. To investigate the contribution of ATR in regulating RNR activity in 
mammals. 
a. To determine the impact of ATR on the expression of RNR subunits. 
b. To explore whether nucleoside supplementation reduces the toxicity 
associated to limited ATR activity. 
c. To investigate whether increased RNR activity can rescue the 
phenotypes of ATR-Seckel mice. 
 
2. To identify new regulators of the mammalian RNR. 
a. To perform proteomic analyses of purified mammalian RNR 
complexes. 
b. To explore if and how the putative interactors of the mammalian 
RNR identified in 2.a suppress replication stress in mammals. 
 
3. To investigate the impact of the RRM1-W684G mutation in mice, which in 
yeast stabilizes the binding of the Rnr to its allosteric inhibitor Sml1. 
a. To generate mice carrying a W684G mutation in Rrm1. 
b. To analyze the impact of Rrm1-W684 heterozygosity or 
homozygosity in mice. 
c. To investigate the mechanisms by which RRM1-W684G expression 
limits the activity of the RNR in mammalian cells. 
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MATERIALS AND METHODS 
1 Mouse work 
1.1 Generation of the Rrm1WG mouse model 
For the generation of RRM1KI mice a 16.8 kb region from the mouse genome which 
targeted the RRM1 gene was first cloned from a BAC (BAC RP23-111K8) into a 
minimal vector (KI construct RRM1, TR#4 R10) by recombineering (Gene Bridges). 
The linearized vector was electroporated into mES cells by the Transgenic Mice 
Unit of CNIO. Properly recombined mES cells were identified by Southern Blot and 
subsequently used for the generation of chimaeric mice. Knock-in mice were 
genotyped by PCR as described below. To remove the Neo-resistance cassette from 
the genome, mice were crossed with constitutive CAG-Flpe transgenic mice 
(Rodriguez et al., 2000). Mice were kept under standard conditions at the specific-
pathogen free facility of the Spanish National Cancer Research Centre in a mixed 
C57BL/6-129/Sv background. All mouse work was performed in accordance with 
the Guidelines for Humane Endpoints for Animals Used in Biomedical Research, 
and under the supervision of the Ethics Committee for Animal Research of the 
“Instituto de Salud Carlos III”.   
Animal genotyping was performed using DNA extracted from small tail pieces that 
were digested for 16 hours at 55°C in lysis buffer: 100 mM NaCl, 20  mM Tris-HCl 
(pH8), 10 mM EDTA, 0.5% SDS and 400 µg/ml (Roche) 400μg/ml. Cellular lysates 
were treated with a saturated NaCl solution and DNA was precipitated with 
isopropanol, washed with 70% ethanol and resuspended in distilled water. 
Genotyping PCRs were performed in a reaction mix composed of 200 μM dNTPs, 
1.5 mM MgCl2, 2μl reaction buffer 10X, 0.15 μl Taq polymerase (Platinum Taq, 
Invitrogen), 0.5 μM of each oligonucleotide and 100ng of genomic DNA. 
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PCR oligonucleotides:  
Rrm1WG(Neo): a band of 135bp for the wt allele and a band of 231bp for the 
Rrm1WG(Neo) allele are expected. 
Fwd: GGCCAGCTTGGCAACTTA 
Rev (Neo): TGGATGTGGAATGTGTGC 
Rev (wt): GAAGTACTGAGATAAACTCC 
Rrm1WG: a band of 231bp for the wt allele and a band of 343bp for the Rrm1WG 
allele are expected. 
Fwd: GGCCAGCTTGGCAACTTA 
Rev: TGCAGTGACTTAGACATCC 
1.2 Southern blot 
Approximately 15 µg of DNA were digested with the MunI (New England Biolabs) 
enzyme for 12 hours at 37°C in a solution containing the digestion buffer provided 
by the manufacturer, 0.1 mg/ml BSA and 2.5 mM spermidine.  Digested material 
was separated by electrophoresis in a 0.8% agarose gel at low voltage until DNA 
was properly separated. The gel was incubated in a 0.25 M HCl solution for 15 
minutes in order to denature the DNA. The gel was treated with 0.4 M NaOH and 
0.6 M NaCl and immersed in 0.5 M Tris-HCl (pH7.5), 1.5 M NaCl neutralizing 
solution for 30 minutes. All treatments were done at room temperature with 
gentle shaking. DNA was transferred by diffusion in 10XSSC (1.5 M NaCl, 0.15 M 
Na3C6H5O7) buffer to a positively charged nylon membrane (Hybond XL, 
Amersham, Buckinghanshire, UK) over night and ultraviolet light was used to 
enhance covalent linkage of DNA to the membrane (Stratalinker, Stratagene, 
Agilent Technologies, Santa Clara, CA). The membrane was prehybridized with a 
hybridizing solution (0.25 M sodium phosphate (pH7.2), 1 mM EDTA, 1% BSA, 7% 
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SDS) at 65°C for a minimum of 2 hours. During this time radioactive labeling of the 
probe was performed. 20 ng of the probe were dissolved in a final volume of 45 µl 
TE. The probe was denaturalized at 99°C and amplified according to the 
instructions of the Random Prime System (Stratagene) with 50 Ci of [32P] dCTP 
and purified by filtration in a Sephadex G-50 Column (ProbeQuant GE Healthcare).  
The membrane-transferred DNA was hybridized to the probe at 65°C overnight in 
a hybridizing solution containing 0.05 mg/ml salmon sperm (Invitrogen). The 
membrane was washed in SSC 2x for 10 minutes, in a SSC 2X, 1% SDS containing 
solution for 30 minutes and finally for another 15 minutes in SSC 0.2X, 0,1% SDS. 
After the washing steps, the membrane was exposed in a cassette to a 
PhosphorImager detection screen for the adequate time and developed with a 
Typhoon TRIO scanner (GE Healthcare). 
1.3 Blood Analysis   
Blood samples were obtained from the sublingual vein and the blood was collected 
in EDTA-treated microtubes (Aquisel). These samples were run on the Abacus 
Junior Vet hematology analyzer (Diatron), providing complete blood counts 
including counts of white blood cells, red blood cells and platelets. 
1.4 Irradiation               
Sublethal irradiation (6 Gy of total body ionizing irradiation) was administered 
(RADSource 2000, X-ray biological irradiator, 160 kV, 4.2 kW, 25 mA) to 8 week 
old mice. The hematologic parameters were then evaluated at 1-5 weeks post 
irradiation. 
2 Cellular biology 
2.1. Cell culture 
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Unless otherwise specified, all cell lines were cultured in DMEM media (4.5 g/L 
Glucose; L-Glutamine) (Lonza, Switzerland) with 10% -15% of inactivated fetal 
bovine serum (FBS) (South American Origin, Lonza) and a mix of penicillin and 
streptomycin (Gibco, Invitrogen, Life Technologies, Carlsbad, CA). Cells were kept 
in incubators at 37°C and 5% C02, except for MEFs, that were maintained in 
hypoxia incubators, at 37°C and 5% C02 and 5% O2. 
2.2 Production of MEFs   
Female and male mice of the desired genotype were mated until vaginal plugs 
were visible. At 13.5dpc of gestation the female was sacrificed and embryos were 
extracted. The fetal liver was removed in sterile conditions, as well as a little piece 
of the head from which DNA was obtained for genotyping. The remaining embryo 
was cut with a sterile blade and incubated 10 minutes in 1ml trypsin 0,25%, EDTA 
(Gibco). The resulting mixture was pipetted up and down in order to dissolve all 
aggregates and neutralized with 9ml cell culture media. The total 10ml were 
transferred to a p100 plate that was kept in hypoxia incubators. The media was 
changed the following day in order to eliminate dead and blood cells.  
2.3 Isolation of splenic B lymphocytes      
Spleenectomy was performed in mice at age 6 to 10 weeks. Whole spleens were 
squeezed in washing buffer: PBS (137 mM NaCl, 2.7 mM KCl, 10  mM Na2HPO4, 
2 mM KH2PO4) with 1% bovine serum albumin (BSA Fraction V, Roche). 
Supernatants were treated with a hypotonic solution (ACK Lysing Buffer, Lonza) 
for 5 minutes, after which the solution was inactivated with washing buffer. 
Cellular aggregates were subsequently eliminated with a 40 m filter and the 
lysate was centrifuged 5 minutes at 350g. The pellet was suspended in 900 l of 
washing solution containing 80 l of anti-CD19 antibody conjugated magnetic 
Mouse CD19 Micro Beads (Miltenyi Biotech, Germany) and incubated at 4°C for 15 
minutes. Cells were washed, suspended in 1 ml washing solution and transferred 
to a separating column (MS Columns, Miltenyi) standing in a magnetic scaffold 
Materials and Methods 
[50] 
 
(OctoMACS separator, Miltenyi). Cells linked to the anti-CD19 beads were 
separated using a magnet (model, brand). After washing the column, these cells 
were eluted outside of the magnetic field. Primary B lymphocytes were maintained 
in culture (1x 106 cells/ml) in RPMI media (Euroclone) supplemented with 10% 
FBS, 1% penicillin/streptomycin (Gibco, Invitrogen), 2 mM glutamine (Gibco, 
Invitrogen), non essential amino acids (Lonza), sodium pyruvate (Gibco, 
Invitrogen), 50 mM β-mercaptoethanol (Gibco, Invitrogen) and 10 mM HEPES 
(Lonza). 25 mg/ml LPS (LPS, Sigma-Aldrich, St. Louis, MO) was added to stimulate 
cells. 
2.4 Proliferation curve 
1.25 x 105 MEFs were seeded in a 35mm plate, after 2 days cells were counted and 
1.25 x105 MEFs were seeded again. The increase in population doublings (PDLs) 
was calculated applying the formula PDLs = log ( nf / n0 ) / log2, where n0 is the 
initial cell number and nf is the final cell number in each passage.  
2.5 Cell cycle analysis     
5x105- 106 cells were harvested as usual; they were fixed with cold PBS 70% 
ethanol over night. Cells were resuspended in a PBS solution containing 1% BSA, 
10 µg/ml propidium iodide, and 0.5 mg/ml RNase A and were analyzed by flow 
cytometry in a FACS Calibur machine (BD).  
2.6 Gene silencing 
Mission endoribonuclease prepared siRNA (esiRNA, Sigma) is a mixture of siRNA 
oligos resulting from cleavage of long double-stranded RNA with dicer. 
Transfection of the esiRNA library or siRNAs targeting human KPNB1 (#1 5´-
CAGUGUAGUUGUUCGAGAUtt, #2 5´-CAUCCGAUAGAAUCCAGUUtt, 3# 5´-CAGCAAG 
UUUUAUGCGAAtt, Ambion) was performed using Lipofectamine RNAimax 
(Invitrogen) according to the manufacturer's instructions. 
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2.7 Protein expression  
Transfection for protein overexpression and viral production were performed with 
Lipofectamine 2000 (Invitrogen), according to the manufacturers standard 
protocols. Viral particles for transduction of human RRM2 or human KPNB1 were 
produced in 293T cells, transfected with a second generation lentiviral platform 
based on the psPax2 pMDEG packaging vectors. At 48 hours post transfection, the 
supernatant from the packaging lines was collected, filtered and added on top of 
experimental cells. 
Stable cell lines of Flp-In T-REx 293 cells (Life Technologies) were generated 
according to the manufacturers instructions. Recombinant protein expression was 
induced by addition of 100 ng/ml doxycycline to the media for the indicated times. 
For the determination of protein half-life, cells were incubated with 25 µg/ml 
cycloheximide (Sigma) for 6/8/10 hours. 
In addition, RRM2, RRM2B, RRM1 and RRM1-WG were expressed in E. coli BL21 
(DE3) (Lifetechnologies). Cells were grown in TB medium at 37°C until the culture 
reached an OD600 of 0.6. Cells were then chilled to 15°C for 30 minutes and 
induced with 0.5 mM IPTG for 18 hours at 15°C while shaking at 220RPM. Cells 
were harvested by centrifugation at 5000 x g for 30 minutes, and cell pellets were 
stored at -80°C.  
2.8 Immunofluorescence/High throughput microscopy (HTM) 
Cells were cultured in 96 well plates with a flat crystal bottom (Greiner Bio-One) 
and treated according to the experimental protocol. Cells were fixed with 2% 
paraformaldehyde in PBS at room temperature for 5 minutes and permeabilized 
with 0.1% sodium citrate and 0.1% Triton X-100 in PBS for 5 minutes. After 
washing three times with 0.25% BSA, 0.1% Tween20 in PBS, cells were incubated 
in blocking solution (2.5% BSA, 0.1% Tween20, 10% goat serum) for 30 minutes. 
The corresponding primary antibody diluted in blocking solution was incubated 
over night at 4 °C. After washing 3 times the secondary antibody conjugated to a 
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fluorophore was added for 1 hour at room temperature, washed and nuclei were 
stained with DAPI. 
When EdU (5-ethynyl 2’-deoxyuridin) staining was required, cells were treated 
with EdU for 30 minutes to 1 hour and fixed with 4 % paraformaldehyde in PBS at 
room temperature for 5 minutes. The Click-iT Edu Cell proliferation Assay kit (Life 
Technologies) was used to stain the incorporated nucleoside.  
Images were automatically acquired from each well by an Opera High-Content 
Screening System (Perkin Elmer). A 20 x magnification lens was used and pictures 
were taken at non-saturating conditions. Images were segmented using the DAPI 
staining to generate masks matching cell nuclei from which the average 
γH2AX/EdU signal was calculated. Data were represented with the use of the 
Prism software (GraphPad Software). 
3 Molecular biology and biochemistry 
3.1 Plasmid construction 
For the construction of pcDNA5/FRT/TO-RRM1 with a C-terminal Strep-tag, the 
cDNA of hRRM1 was amplified by PCR from human cDNA and cloned into pEXPR-
IBA103 (Novagen) vector at SacII/XhoI sites. From there, the RRM1-Strep 
sequence was PCR amplified adding AflII/NotI restriction sites for subsequent 
cloning into the pcDNA5/FRT/TO vector (Life Technologies). Expression plasmids 
for RRM1-WG were constructed by introducing the W684G mutation into the wild-
type pEXPR-IBA103 expression plasmid using the Quick Change site-directed 
mutagenesis kit (Agilent Technologies) followed by PCR and subcloning into the 
pcDNA5/FRT/TO vector as described above. The final constructs were sequenced 
to rule out the presence of mutations. The plasmids coding for KPNB1, RRM2 and 
the empty vector were obtained from the Precision LentiORFTM collection 
(Dharmacon). 
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For bacterial expression, the cDNAs of human RRM1, RRM1-WG, RRM2 and 
RRM2B were cloned into the pET30a expression vector at SalI/NotI (RRM1 and 
RRM1-WG) or BamHI/XhoI (RRM2 and RRM2B) RS sites and expressed as 
6xHistidine-tagged (His-tag) versions in Bl21 cells. In addition, RRM1 and RRM1-
WG were expressed as a Streptavidine-tagged (Strep-tag) version by removal of 
the N-terminal His-tag and introduction of a Strep-tag into the pET30a vector.  
3.2 Western blot 
The following primary antibodies were used:  Strep-Tag II (Novagen, 71590-3), 
RRM2B (Abcam, ab8105) RRM2 (Santa Cruz, Sc-10844), RRM1 (Cell Signaling, 
3388), and β-Actin (Sigma, A5441), CHK1 (Novocastra), CHK1-S345P (Cell 
Signaling Technology, 2348S), RPA (Abcam, ab2175), RPA-S4P/S8P (S4/S8) 
(Bethyl, A300-245A) and γH2AX (Upstate, 05-636), KPNB1 (Abcam, ab2811), HIS 
(Rockland 600-401-382). 
For extraction of whole cell lysates, cells were lysed for 10 minutes on ice in RIPA 
buffer (50 mM Tris-HCl (pH7.4), 1% NP-40, 0.25% Na-deoxycolate, 150 mM NaCl 
and 1 mM EDTA)  supplemented with protease and phosphatase inhibitors (Sigma-
Aldrich) and centrifuged at 16000g to eliminate cell debris. Cytosolic and nuclear 
extracts were prepared as previously described (Lecona et al., 2008). Bradford 
method was used to determine protein concentration. Extracts were denatured in 
NuPage loading buffer (Lifetechnologies) heated for 10 minutes at 75°C, and 
separated in gradient gels 4-12% SDS-PAGE (Tris-Acetate Nupage Novex, 
Invitrogen). Proteins were subsequently wet-transferred to nitrocellulose 
membranes (Hybond ECL Nitrocellulose, Amersham). After transfer, membranes 
were incubated for 30 minutes at room temperature in blocking solution (5% 
skimmed milk, Central Lechera Asturiana) in 0.1% TBS-Tween20 (TBS-T). 
Membranes were incubated overnight at 4°C with primary antibodies diluted in 
TBS-T 5% BSA. After washing the membranes 3 times with TBS-T, they were 
incubated for 1 hour at room temperature with HRP-conjugated secondary AB. 
Proteins were visualized with SuperSignal West Pico or Femto Chemiluminescent 
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Substrate (Lifetechnologies) on a ChemiDoc XRS Gel Photo Documentation System 
(Bio-Rad). 
3.3 Immunoprecipitation 
For protein Immunoprecipitation from Flp-In T-REx 293 cells, cells were washed 
once with PBS, and lysed in RIPA buffer (50 mM Tris-HCl (pH7.4), 1% NP-40, 
0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA ) containing protease and 
phosphatase inhibitors (Sigma) followed by centrifugation at  16000xg for 30 
minutes to produce clear lysate. The supernatant was loaded on a Micro Bio-Spin™ 
Chromatography Columns (Bio-Rad) and incubated with Strep-Tactin Macroprep 
Resins (Iba) for 2 hours at 4°C on a rotator. The column was washed 5 times with 
buffer W (100 mM Tris-HCl (pH8), 1 mM EDTA, 200 mM NaCl) containing 0.1% 
NP-40. RRM1 or RRM1WG and associated proteins were eluted with 2mM Biotin in 
buffer W. 
3.3.1 Recombinant protein purification 
For the isolation of recombinant protein from bacteria, cells were thawn on ice and 
resuspended in washing buffer (50 mM Tris (pH7.8), 200 mM NaCl, 2 mM PMSF 
and 1 mM dithiothreitol (DTT)).   
Cells were ruptured by sonication cycles at 4°C and centrifuged at 30000g for 30 
min at 4°C. The supernatant was incubated with Ni-NTA agarose (Qiagen) or Strep-
Tactin Macroprep Resins for 1 hr at 4°C on a rotator and loaded onto a biospin 
disposable chromatography column. For purification of Strep-tagged proteins, 
beads were washed 3 times with washing buffer and bound protein was eluted 
with washing buffer containing 2 mM biotin. For the purification of His-tagged 
proteins, 10 mM imidazole was added to the washing buffer and samples were 
eluted in buffer containing 250 mM imidazole. 
Fractions were analyzed for purity using a 12% SDS-PAGE gel and coomassie 
staining. Fractions containing RRM1, RRM1-WG, RRM2 or RRM2B were pooled and 
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dialysed against 50 mM Tris (pH7.8), containing 200 mM NaCl, 2.5 mM, 2 mM 
PMSF, 10% glycerol and purified proteins were stored at -80°C. 
3.4 In-vitro binding assay 
Generally, 1,5µg Strep-RRM1 or Strep-RRM1-WG and 1,5µg of indicated His-RNR 
subunits were mixed in 0,5 ml of IP buffer (25 mM Tris-HCl (pH7,5), 200 mM NaCl, 
1 mM EDTA, 2 mM PMSF, 1 mM DTT) and incubated for 20 minutes at RT. Strep-
tactin beads were added and samples incubated for 1.5 hours under constant 
rotation at 4°C. Beads were washed 5 times and bound proteins were eluted in IP 
buffer containing 2 mM biotin. Proteins were separated on a SDS gel and stained 
with coomassie or analyzed by WB.  
3.5 RNA extraction and analysis 
Total RNA was isolated using Absolutely RNA Microprep Kits (Agilent) according 
to manufacturers recommendations. Samples harvested at different time points 
were stored in lysis buffer at -80°C and extraction was performed at the same time 
for all samples. After the extraction, samples were stored at -80°C. 
cDNA was synthesized using the SuperScript II Reverse Transcriptase kit for RT–
PCR (Invitrogen). Real-time PCR was performed using the SYBR-Greener qPCR 
Supermix (Invitrogen) in the Cycler Real Time PCR System (BioRad). GAPDH 
expression level was used to normalize values of gene expression. Data are shown 
as fold change relative to the sample control and at least two independent 
experiments in triplicate were performed. The oligonucleotides used were:  
GAPDH Fwd: GCCACCCAGAAGACTGTGGATGGC 
GAPDH Rev: CATGATGGCCATGAGGTCCACCAC 
RRM1 Fwd: TGTGGATCAAGGTGGAAACA  
RRM1 Rev: GGGATCCAAAGTGCAAAGAA 
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RRM2 Fwd: CCTACTAACCCCAGCGTTGA 
RRM2 Rev: GTTTCAGAGCTTCCCAGTGC 
RRM2B Fwd: TACAAGCAAGCACAGGCATC 
RRM2B Rev: CGCTCCACCAAGTTTTCATT 
3.6 dNTP measurements 
For LC-MS/MS analysis of cytosolic fractions the instrument consisted of an 
Acquity Ultra Performance LC and a Xevo TQ using an ESI source operated in 
negative mode (Waters, Sollentuna, Sweden). 200 μl of 60% acetonitrile in water 
containing 100 mM ammonium acetate and 10 mM ammonium phosphate was 
added to five million cells followed by 10 minutes of sonication using an Ultrasonic 
Cleaner 5510 (Branson Ultrasonics, Danbury, CT) to lyse cell membranes and 
precipitate the proteins. After centrifugation, 20 μl of the supernatant was injected 
on a ZIC-cHILIC column (100x2.1 mm, 3 μm, Merck-Millipore, Sollentuna, Sweden) 
termostated at 30 °C. dNTPs were separated using a six minute gradient from 65 to 
50% acetonitrile at a flow rate of 400 μl/min. 
For DNA Polymerase assays two million MEF were resuspended in 60% methanol, 
frozen in liquid nitrogen and boiled for 3 minutes. Samples were evaporated until 
dryness in a speedvac and whole cell levels of dNTPs were determined using the 
DNA polymerase assay previously described (Desler et al., 2007).  
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RESULTS 
1 Initial evidences for a connection between ATR and the RNR 
ATR, like its yeast ortholog Mec1, is essential for cell viability since it is the main 
kinase controlling checkpoint signaling during the cell cycle and in response to 
DNA damage (Elledge, 1996; Weinert, 1998). In contrast to ATR, the essential 
function of Mec1 is well understood and consists in the positive regulation of the 
dNTP pool through induction of RNR activity. In S.cerevisiae, Mec1 activation leads 
to phosphorylation and subsequent degradation of the RNR inhibitor Sml1, 
resulting in an increase of RNR activity and dNTP levels. Importantly, deletion of 
Sml1 rescues the viability of mec1Δ mutants, strongly suggesting that the essential 
role of Mec1 is related to RNR activity (Zhao et al., 2001; Zhao and Rothstein, 
2002). Whereas RNR subunits are highly conserved from yeast to humans, 
including the sequence surrounding the binding site of Sml1 to Rnr1, no allosteric 
inhibitors of the canonical RRM1-RRM2 complex have been described in mammals. 
However, several evidences suggest that the ATR-dependent regulation of the RNR 
could be to some extent conserved in mammals. First, addition of nucleosides has 
been shown to reduce oncogene-induced RS in mammalian cells (Bester et al., 
2011). Second, a recent paper directly linked ATR signaling to RRM2 stability 
(D'Angiolella et al., 2012). Third, the transcriptional regulation of RNR genes by 
ATR is similar in mammals and yeast. Here, we wanted to explore to what extent 
the ATR-dependent control of the RNR and dNTP pools is conserved in mammals. 
While Rrm2 expression has been directly linked to ATR signaling (Zhang et al., 
2009), Rrm1 expression had only been linked to ATM activity, the main checkpoint 
kinase responsible for signaling DNA DSBs (Eaton et al., 2007). To explore in detail 
the impact of ATR signaling on the transcription of the different RNR subunits, we 
measured their mRNA expression levels in response to conditions that either 
induce or inhibit ATR signaling. On one hand, the RS checkpoint was abrogated 
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using chemical inhibitors of ATR (Toledo et al., 2011) or CHK1 (UCN-01). On the 
other hand, ATR signaling was induced by the usage of HU, an inhibitor of the RNR 
that quickly induces RS by nucleotide depletion and hence activates ATR signaling. 
In addition, we took advantage of a cellular system (3T3-TopBPI-ER) in which ATR 
can be activated in response to tamoxifen (4-OHT), and in the absence of any actual 
DNA damage (Toledo et al., 2008). Expression of Rrm1, Rrm2 and Rrm2b were 
induced in response to HU, while inhibition of CHK1 repressed Rrm1 and Rrm2 
expression (Figure 8A). In contrast, Rrm2b was induced in response to CHK1 
inhibition, potentially caused by CHK1i-induced DNA breaks. Importantly, 
inhibition of ATR or CHK1 repressed Rrm1 expression while its activation induced 
Rrm1 (Figure 8B). Our results show a clear correlation between ATR activity and 
expression of both RNR subunits involved in DNA replication, Rrm1 and Rrm2. 
Together our data indicate that ATR indeed regulates not only transcription of 
Rrm2 but also of Rrm1, confirming a link between ATR and the RNR in mammals.  
 
Figure 8: ATR regulates the expression of the RNR subunits Rrm1, Rrm2 and Rrm2b. (A) 
Expression of Rrm1, Rrm2 and Rrm2b were induced in response to HU, while inhibition of CHK1 
(CHK1i) repressed Rrm1 and Rrm2 expression but induced Rrm2b. Cells were treated where 
indicated for 8 hours with 2mM HU or 300nM UCN-O1 (CHK1i). (B) ATR was activated upon 
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tamoxifen (OHT) treatment (Toledo et al., 2008) and induced Rrm1 expression while its inhibition, 
as well as inhibition of CHK1, repressed Rrm1.  
Interestingly, the results were further supported by available data from our lab 
that showed a correlation between Rrm2 expression and ATR in mice. The murine 
model for the ATR-Seckel Syndrome previously developed in our lab (Murga et al., 
2009) presents severely reduced ATR activity resulting in increased RS, stunted 
growth and premature aging (Monasor et al., 2013; Murga et al., 2009). Microarray 
data from this study revealed reduced levels of Rrm2 expression in ATR mutant 
embryonic livers and brains, indicating that low Rrm2 expression might contribute 
to the ATR-Seckel phenotype (Murga et al., 2009). Taken together, our results 
point towards a connection between ATR function and RNR activity in mammals 
and prompted us to explore whether increasing RRM2 expression could alleviate 
the physiological consequences of reduced ATR activity in mice. 
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2 Increased Rrm2 gene dosage reduces RS and prolongs survival of 
ATR deficient mice 
2.1 Nucleosides limit RS and improve growth of ATR-Seckel MEFs 
As mentioned before, early studies in yeast had shown that Mec1 deficiency could 
be rescued by situations that increase cellular dNTP levels, such as overexpression 
of RNR or exogenous supply of nucleotides, indicating that stimulation of dNTP 
production is an essential function of Mec1. Along these lines, a recent study also 
shows that oncogene-induced RS can be reduced by exogenous supply of 
nucleotide precursors in mammalian cells (Bester et al., 2011). To determine 
whether a reduced pool of dNTPs could underly the accumulation of RS and 
growth defects of ATR-Seckel cells, we first tested the effect of an exogenous 
supply of nucleosides. RS levels can be rigorously quantified via high-throughput 
microscopy (HTM) by measuring ATR-dependent H2AX phosphorylation (γH2AX) 
(Murga et al., 2011; Toledo et al., 2011). Our results showed that an extra supply of 
nucleosides significantly reduced levels of RS in ATR-Seckel MEF and partially 
recovered their growth rates (Figure 9).  
 
Figure 9: Nucleoside supplementation reduces RS and improves growth of ATR-Seckel MEF. 
(A) HTM-mediated quantification of the intensity of γH2AX per individual nucleus on Atr+/+ and 
AtrS/S MEF treated in the absence or presence of nucleosides (60μM) for 24 hours. Data are 
representative of 2 independent cell lines. (B) Proliferation curves of Atr+/+ and AtrS/S MEF grown in 
the presence or absence of nucleoside supplementation (60μM). Data are representative of two 
independent analyses (Lopez-Contreras et al 2015). 
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These initial studies suggested that increased levels of nucleotides could 
potentially suppress the physiological consequences of reduced ATR activity in 
mammals. 
2.2 RRM2 overexpression protects from reduced ATR activity in vitro and 
in vivo 
We next explored whether genetic manipulations that stimulate RNR activity could 
also rescue phenotypes linked to limited ATR activity in mammals. To this end, we 
generated a U2OS cell line stably overexpressing RRM2. We selected RRM2 for the 
following reasons: first, RRM2 is rate limiting for mammalian RNR activity (Lewis 
and Wright, 1974; Tonin et al., 1987); second, RRM2 is stabilized in response to 
ATR signaling after DNA damage (D'Angiolella et al., 2012); finally, the previously 
mentioned microarray data from our lab pointed towards a potential correlation 
between reduced Rrm2 expression and phenotypes caused by ATR deficiency 
(Murga et al., 2009). To test whether RRM2 overexpressing cells exhibit increased 
RNR activity, we examined their response to the RNR inhibitor HU.  HTM analyses 
revealed that RRM2 overexpressing cells exhibited lower levels of γH2AX and 
phosphorylation of RPA and CHK1 in response to HU (Figure 10A) while cell 
replication was not altered (Figure 10B), confirming an increased RNR activity in 
those cells. Depletion of the RNR subunits had the opposite effect (Figure 10C,D). 
Importantly, RRM2 overexpressing cells also exhibited reduced levels of γH2AX in 
response to ATR or CHK1 inhibitors (Figure 10A). Together, these results show 
that overexpression of RRM2 leads to enhanced RNR activity in mammalian cells 
and that this confers increased resistance to the replicative damage induced by 
limited ATR/CHK1 signaling. 
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Figure 10: RRM2 overexpression reduces RS levels. (A) HTM-mediated quantification of the 
intensity of γH2AX per individual nucleus on human U2OS cells overexpressing RRM2, or the empty 
vector (Control). Where indicated, cells were also exposed to the indicated concentrations of HU, 
CHK1i or ATRi for 3 hours. (B) HTM-mediated quantification of EdU uptake. Cells were labeled with 
EdU for 1 hour. (C) HTM-mediated quantification of the intensity of γH2AX per individual nucleus 
on human U2OS cells 48 hrs after being transfected with either a scrambled control esiRNA 
(Control) or esiRNAs targeting RRM1 or RRM2. Where indicated, cells were also exposed to HU 
(2mM) for 3 hours. Data is representative of three independent experiments. (D) Western blot 
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illustrating the impact of RRM2 overexpression (RRM2) or depletion (si-RRM2) on RPA and CHK1 
phosphorylation in U2OS cells. Ponceau is shown as a loading control. HU was added for 3 hours 
where indicated. 
Given that we observed increased resistance towards ATR inhibitors in cells with 
elevated RNR activity, we explored the effects of ATR inhibition on cellular dNTP 
levels. To this end we measured dNTP levels in NIH 3T3 cells after exposure to HU 
or ATR inhibitors. Remarkably, two independent methods of dNTP quantification 
revealed that ATR inhibition leads to a reduction in cellular dNTP levels (Figure 
11A,B). The greater effect of HU on dATP and its impact on dTTP levels is 
consistent with previous literature (Julias and Pathak, 1998). These results reveal 
that an exhausted dNTP pool could contribute to the toxicity of ATR inhibitors. 
 
Figure 11: Nucleotide concentrations in response to ATR inhibition. dNTP levels were 
measured by two independent methods: liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS)(A) or a DNA polymerase assay. (A) LC-MS analysis represents cytosolic 
dNTP levels and (B) DNA Polymerase assays whole cell levels. Analyses were performed on NIH 
3T3 cells exposed to HU (2mM, 6 hours) or ATRi (1µM, 6 hours). In (A), dGTP levels were 
undetectable. Each figure depicts one representative analysis where biological triplicats were 
analysed in parallel (Lopez-Contreras et al., 2015). 
Finally, after confirming that increased RRM2 levels reduced the toxicity of ATR 
inhibitors, we sought to investigate the consequences of increased RNR activity in 
vivo. To this end, Andres López-Contreras in the laboratory generated mice 
carrying an extra allele of the RRM2 subunit (Rrm2TG). In agreement with our 
results obtained in U2OS cells, Rrm2 transgenic cells showed increased RNR 
activity and an increased resistance towards ATR inhibitors (Lopez-Contreras et 
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al., 2015). When crossed with ATR-Seckel mice, the presence of the Rrm2 
transgene significantly reduced the ATR-Seckel associated phenotypes such as 
reduced body size and craniofacial abnormalities. Importantly, ATR-hypomorphic 
mice carrying an extra allele of Rrm2 doubled the median life span of their 
littermates lacking the Rrm2 transgene (50 weeks vs. 24 weeks) and increased the 
maximum life span from 54 weeks to 91 weeks (Figure 12). Taken together, our 
results show that, similar to yeast, ATR deficiency can be partially rescued by 
increased RNR activity in mammals (Lopez-Contreras et al., 2015).  
 
Figure 12: Kaplan-Meier curves of  ATRS/S;Rrm2+/+ (n = 25) and ATRS/S; Rrm2+/TG (n = 26) 
mice. The p value was calculated with the Mantel-Cox log rank test (Lopez-Contreras et al., 2015). 
In conclusion, we have shown that overexpression of the RRM2 subunit leads to 
increased RNR activity in mammals and it confers resistance towards replicative 
damage induced by ATR deficiency. Furthermore, our results indicate that part of 
the toxicity caused by ATR inhibitors might be due to reduced dNTP levels. 
Together, these results point towards a conservation of the ATR-dependent 
regulation of the dNTP pool through regulation of RNR in mammals. 
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3 Exploring new interactors for the RNR 
As described, RNR is an evolutionary well conserved, highly regulated protein 
complex whose activity is controlled by Mec1, allosteric inhibitors, and nuclear 
sequestration in fission and budding yeast (see Introduction 2.2.2). Given that 
the post-transcriptional regulation of mammalian RNR remains poorly defined, we 
decided to search for new interactors of the mammalian RNR by MS. We employed 
various experimental approaches in order to purify the different RNR subunits as 
well as the whole RNR complex. First, we generated  constructs comprising human 
RRM1 or RRM2 with a C-terminal Twin-Streptavidine-tag (Strep-tag) that were 
expressed in the FlpIn T-REx 293 cell line, a system allowing for homogeneous and 
doxycycline-inducible expression of a given cDNA from a single integration site 
(Figure 13).  
 
Figure 13: Generation of RRM1 or RRM2 overexpressing cell lines. The human cDNA of RRM1 
or RRM2 was cloned upstream of a 2 x Strep-tag into the pcDNA5-FRT/TO expression vector. 
Transfection of the pcDNA5-FRT/TO construct in parallel with the FLP recombinase leads to 
integration into a single site in the genome of the FlpIn T-REx 293 cell line. A stable cell line 
carrying the pcDNA5-FRT/TO-RRM1/2 plasmid was selected with hygromycin. Expression of the 
construct is repressed by the Tet repressor in the absence of the inducer doxycycline. 
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In order to identify proteins that interact with the RNR subunits, we performed 
Strep IP from lysates of the RRM1-Strep or RRM2-Strep FlpIn T-Rex 293 cells and, 
with the help of the Proteomics Unit of CNIO, analyzed samples by mass 
spectrometry (MS). As expected, RRM1 was the protein identified with the highest 
score after RRM1-Strep pull-down, followed by RRM2 and RRM2B. However, MS 
data also revealed an about 30 fold enrichment of the purified RRM1-Strep 
peptides over its RNR complex binding partners, most likely due to the high 
overexpression of the recombinant protein. This brought us to speculate, that the 
overexpression of only one subunit might yield physiologically irrelevant results 
since free RRM1-Strep or RRM2-Strep rather than the active complex might be 
purified. On the basis of the fact that we were looking for proteins interacting with 
and regulating the activity of the RNR holocomplex, we aimed to improve the 
method in order to purify the entire RNR complex. To this end, we designed an 
expression vector, where we introduced an internal ribosomal entry site (IRES) 
followed by an N-terminally Flag-tagged RRM2 behind the RRM1-Strep sequence 
(Figure 14A). This approach allowed the expression of similar levels of RRM1-
Strep and Flag-RRM2, and the purification of the whole complex by serial Strep-
Flag-IP (Figure 14B). The complex was expressed and purified in a ratio of 1:2,5 
for RRM1:RRM2, indicating that we enriched for the physiological RNR complex 
(Figure 14C,D). We followed a similar approach to purify the alternative RNR 
complex, RRM1-RRM2B. MS analysis showed that the RRM1-RRM2B complex 
could also be efficiently purified (Figure 14E). In all cases we could detect the co-
precipitation of the alternative small subunit (RRM2B and RRM2 for pull-down of 
RRM1-RRM2 and RRM1-RRM2B respectively) indicating that the method worked 
reliably. Unfortunately, looking at the ensemble of our experiments, no consistent 
and common new protein interactor of the RNR could be identified.  
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Figure 14: Purification of the RNR complex. (A) pcDNA5-FRT/TO expression construct 
comprising the C-terminally tagged human Rrm1 sequence followed by an internal ribosomal entry 
site (IRES) and the Flag-tagged human Rrm2 sequence. (B) Experimental pipeline for the 
purification of the RNR complex from the RRM1-Strep-Flag-RRM2 expressing FlpIn T-REx cell line. 
(C) WB analysis of immunoprecipitated RNR complex. FT = flow through, Elution 1 = pull down of 
Strep-RRM1, Elution 2 = pull down of Flag-RRM2. (D) Mass spectrometry data showing the 
purification of the RRM1-RRM2 complex. (E) Mass spectrometry data showing the purification of 
the RRM1-RRM2B complex. PSM = peptide spectrum match. 
3.1 A genetic screening for RNR interactors 
Even though no consistent new interaction partners of the RNR could be identified 
in our pull-down experiments, we reasoned that some of the weak interactors 
found in our proteomics could be bona-fide regulators of the RNR. In agreement 
with this, we were able to identify cyclinF, and members of the APC or SCF 
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ubiquitin ligases in our experiment (Table 1), which are known regulators of RNR 
levels (Chabes and Thelander, 2000; Chabes et al., 2003b; D'Angiolella et al., 2012). 
We thus decided to select a number of candidates for a subsequent genetic 
screening from the list of proteins identified by MS, further exploring their effect 
on RNR activity. To this end, we subjected the list of potential RNR interactors to 
an academically informed examination. Based on their described function (e.g. 
replication, damage response, signaling or nuclear import), we selected 56 
candidate genes for further investigation (Table 1).  
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Table 1: List of candidate genes selected based on results obtained from the RNR pull-down 
experiments, and targeted in the genetic screening. Gene functions selected include but are not 
limited to DNA replication and repair, transcription factor and nuclear import. Genes known to 
interact with the RNR are highlighted in red. 
Next, we designed a screening approach that would allow to functionally test 
whether any of the candidate genes could modulate RNR activity in cells. The 
screening strategy included the targeting of the candidates with Endoribonuclease-
prepared siRNAs (esiRNAs) followed by treatment with a low dose of the RNR 
inhibitor HU. Targeting of a gene that induces or inhibits RNR activity would result 
in reduced or increased levels of HU-induced γH2AX (Figure 15A). As a proof of 
principle, when RRM1 or RRM2 were targeted by esiRNAs, their downregulation 
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led to a significant increase in HU-induced γH2AX (Figure 15B). Following this 
pipeline, we identified one protein, Karyopherin-beta 1 (KPNB1), the depletion of 
which severely induced RS in response to RNR inhibition (Figure 15B).  
 
Figure 15: Screen for functional RNR-regulators. (A) Candidate genes were targeted by esiRNA 
transfection of U2OS cells. 48 hours after transfection, cells were treated with low doses of the RNR 
inhibitor HU, stained for γH2AX, and analyzed using the Opera HTM platform (B). A.U. = Arbitrary 
Units, n.t. = non transfected, FLUC = firefly luciferase (control). Data are representative of 3 
independent experiments.  
KPNB1, or importin-beta 1, is a nuclear importer that belongs to the importin-β 
family which consists of about 20 members in human. KPNB1 binds either directly 
or through karyopherin-alpha1 (KPNA1) to the nuclear localization signal (NLS) of 
its substrates, which are consequently shuttled into the nucleus via a RAN-GTP 
dependent mechanism. KPNB1 regulates a number of cellular functions such as cell 
cycle, mitosis and replication through the nuclear import of its substrates  
(Mosammaparast and Pemberton, 2004). Our results suggest a novel function for 
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KPNB1 in the regulation of the RS-response and a potential role in regulating RNR 
activity. 
3.2 KPNB1 suppresses RS  
In order to confirm our results for KPNB1 obtained in the genetic screening, we 
repeated the experiment above with 3 independent siRNAs targeting KPNB1. 
Depletion of KPNB1 by any of the three siRNAs increased the levels of γH2AX, 
which could be further increased by previous treatment with HU (Figure 16). 
 
Figure 16: KPNB1 depletion induces RS. (A) HTM-mediated quantification of γH2AX intensity per 
nucleus in U2OS cells transfected with a scrambled control siRNA (si-SCRMBL) or one of three 
different siRNAs against KPNB1 (si-1-KPNB1, si-2-KPNB1 and si -3-KPNB1) and treated with HU for 
4 hours. (B) HTM-mediated quantification of γH2AX intensity per nucleus in U2OS cells transfected 
with a scrambled control siRNA or a pool of the three siRNAs targeting KPNB1 (si-KPNB1-1,2,3) 
and treated with HU for 4 hours where indicated. Data from three independent experiments is 
shown. A.U. = Arbitrary Units. (C) WB of KPNB1 showing depletion in cells treated with a siRNA (si-
1-KPNB1) against KPNB1.  
To determine whether the role of KPNB1 on RS was direct, we tested whether its 
overexpression could increase the resistance towards RS. We generated a stable 
U2OS cell line overexpressing either KPNB1 or an empty control vector (Figure 
17A). Importantly, whereas KPNB1 expression did not affect DNA replication, as 
measured by EdU incorporation (Figure 17B), it significantly reduced HU-induced 
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H2AX levels (Figure 17C). In summary, our results illustrate that KPNB1 
suppresses HU-induced RS in human cells. 
 
Figure 17: KPNB1 overexpression reduces RS. U2OS cells were infected with a lentivirus for 
KPNB1 or an empty vector (Control) and expression was validated by WB (A). (B) HTM-mediated 
quantification of EdU intensity per nucleus in control cells and cells overexpressing KPNB1. (C) 
Cells overexpressing either KPNB1 or empty vector were treated for 4 hours with 1mM HU and RS 
levels were quantified by HTM-mediated quantification of γH2AX intensity per nucleus. The 
experiment was done in duplicate and represents data of three independent experiments. 
3.3 How does KPNB1 reduce RS? 
Given that KPNB1 is a nuclear importer and that it was initially identified as a 
protein co-precipitating with RNR, we speculated that KPNB1 might facilitate the 
nuclear import of the RNR subunit(s) as a way to confer resistance towards RS. 
Moreover, studies in yeast that were published during this PhD identified a role for 
the yeast ortholog of KPNB1 in the translocation of RNR (Dosil, 2011).  However, 
no difference in the distribution of RNR could be detected between control and 
KPNB1 deficient cells (Figure 18). Interestingly, and by reasons that remain to be 
determined, KPNB1 depletion reduced the expression of RRM2 and RRM2B.  
Results 
[74] 
 
 
Figure 18: KPNB1 levels do not affect nuclear localization of RRM2. U2OS cells were 
transfected with a scrambled control siRNA (SCRBL) or siRNA targeting KPNB1, and after 48 hours 
cytosolic and nuclear fractions were analyzed by WB for RRM2 and RRM2B levels. Where indicated 
cells were treated with 2 mM HU for 4 hours. 
Here we tried to identify new regulators of the mammalian RNR. In conclusion, our 
results suggest that the RNR is a rather stable complex composed of the RRM1, 
RRM2 and RRM2B subunits which do not seem to interact with other specific 
proteins at equimolar ratios. This study has also led to the identification of KPNB1 
as a suppressor of HU-induced RS, although the mechanism remains to be defined.  
 
Results 
[75] 
 
4 A mouse model for the ribonucleotide reductase subunit 1 
So far, we could show that indeed, the ATR–dependent regulation of RNR activity 
seems to be conserved in mammals to a large extent. However, the functional 
connection that links ATR to RNR remained elusive. As we have detailed before, an 
important factor that mediates the Mec1-dependent control over RNR in 
S.cerevisiae is its allosteric inhibitor Sml1. While no mammalian ortholog for Sml1 
is known, the sequence surrounding the binding site of Sml1 to Rnr1 is well 
conserved and recombinant yeast Sml1 has been shown to bind and inhibit 
mammalian RRM1 in vitro (Chabes et al., 1999; Zhao et al., 2001). In 2000, 
Rothstein and colleagues described a point mutation in the rnr1 gene (rnr1-
W688G) in S.cerevisiae that leads to increased constitutive binding to Sml1 
(Georgieva et al., 2000). The W688G mutation was originally identified based on its 
ability to physically interact with Sml1 mutants with compromised binding to wt 
Rnr1 (Georgieva et al 2000). The point mutation locates to a small alpha-helical 
region on the outside surface of the Rnr1 protein (Figure 19A) (Uhlin and Eklund, 
1994), a region involved in the interaction of the Rnr1-NTD with Sml1 and the 
Rnr1-CTD (Zhang et al., 2007). Mutation of the Trp-688 to glycine caused a specific 
increase in Sml1 binding to Rnr1, resulting in reduced RNR activity, dNTP levels 
and cell viability; all of which could be rescued by concurrent deletion of Sml1 
(Andreson et al., 2010; Georgieva et al., 2000). Interestingly, the sequence 
surrounding the point mutation is highly conserved from yeast to humans (Figure 
19B). We hypothesized that if a mammalian ortholog of Sml1 were to exist, 
introducing this mutation into the mouse genome might lead to increased binding 
of this factor to RRM1. In addition, such a mouse model would have constitutively 
lower levels of nucleotides, providing an interesting model to explore the role of 
nucleotide pools in mammalian health. We were particularly interested in testing 
whether Rrm1-W684G mice (from now on Rrm1-WG) would present a phenotype 
similar to yeast rnr1-W688G, such as reduced RNR activity and dNTP levels. 
Moreover, no loss-of-function mouse model of the RNR existed. Hence, we 
generated a mouse knock-in (KI) strain carrying the W684G mutation in Rrm1. 
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Figure 19: The WG point mutation is evolutionary conserved. (A) 3-D structure of E.coli R1. The 
position of the conserved W670 corresponding to W688 in yeast and W684 in mouse is indicated 
with a white arrow. The active site is shown in green and the two redox active cysteines are shown 
in red (Georgieva et al., 2000). (B) Pairwise local alignments of yeast (Saccharomycis cerevisiae) and 
mouse (Mus musculus) RRM1 protein sequences surrounding the point mutation. 
4.1 Generation of the Rrm1WG mouse model 
Gene targeting into a desired genomic location allows for the genetic modification 
of a specific target sequence. We decided to use this method to generate a KI 
mouse model carrying the Rrm1W684G point mutation. The mouse Rrm1 gene is 
located to chromosome 7, has a total length of 28 kb and consist of 19 exons with 
W684 locating to exon 18. We designed a 16,8 kb construct containing exons 14-19 
carrying the Rrm1W684G mutation (TGG → GGC) and including downstream 
sequences of the Rrm1 gene (chr7:102,460,313-102,481,519) (Figure 20).  
 
 
 
A 
A 
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Figure 20: KI construct RRM1. (A) Rrm1 knock-in construct comprising a FRT-neo-FRT resistance 
cassette and exon 18 harbouring the W684G point mutation flanked by two 6kb homology arms. 
The vector was linearized with SacII and NotI and electroporated into ES cells. (B) Genomic 
integration site within Rrm1 and location of the W684G point mutation. 
 
The construct was generated by recombineering (GeneBridges) and the linearized 
Rrm1-WG targeting vector was electroporated into mouse embryonic stem (ES) 
cells by the Transgenic Mice Unit of the CNIO. The presence of a Frt-Neo-Frt 
resistance cassette allowed to select successfully transfected ES cells with 
Neomycin resistance. ES cell lines carrying the Rrm1-WG mutation were identified 
by southern blotting and one line (Rrm1WG(Neo)) carrying the correct integration 
was selected (Figure 21). 
 
Figure 21: Strategy and identification of Rrm1+/WG(Neo) ES cells. (A) Schematic figure of Southern 
blot strategy indicating the restriction sites for MunI and the binding sites of the radioactively 
labeled probes. (B) Southern blot with an external (5´Probe) and internal (3´Probe) Rrm1 probe, 
illustrating the presence of an integration site (15,5 kb and 9,5 kb respectively) on the Rrm1WG (Neo) 
strain. The 23,3 kb band corresponds to the endogenous Rrm1.  
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The Rrm1WG(Neo) ES cell line was subsequently used for the aggregation with 
blastocyst stage embryos followed by implantation into a pseudo pregnant female 
and a chimeric Rrm1WG(Neo) founder line was established. Rrm1WG(Neo) KI lines were 
identified by PCR using primers annealing to the sequence coding for the neomycin 
resistance gene within the targeting vector. To remove the Neo-resistance cassette 
from the genome, Rrm1WG(Neo) mice were crossed with CAG-Flpe transgenic mice 
that express the enhanced version of the FLP recombinase under the control of the 
synthetic CAG promoter providing ubiquitous expression in all tissues (Rodriguez 
et al., 2000). FLP recombinase detects the FRT-FRT sites flanking the resistance 
cassette and mediates recombination that will result in deletion of the FRT-flanked 
Neomycin resistance gene in the offspring (Figure 22).  
 
Figure 22: FLP recombinase mediated removal of the Neomycin cassette. Crossing of 
Rrm1WG(Neo) mice with CAG-FlpeT/T animals leads to FLP-recombinase dependent removal of the 
Neo-resistance cassette (red arrow) in the offspring using the FRT sites (black triangle).  
Accordingly, Rrm1WG(Neo) mice were bred with CAG-FlpeT/T mice in order to remove 
the resistance cassette. Removal of the Neomycin cassette was confirmed by PCR 
and a new Neo-cassette free line, Rrm1WG, was established. All subsequent 
experiments described in the thesis were done with this line, which only carries 
the Rrm1-W684G mutation and an FRT in its genome. 
 
 
Results 
[79] 
 
4.2 The Rrm1-W684G mutation causes early embryonic lethality in mice 
The yeast rnr1-WG point mutation causes increased binding of Sml1 to Rnr1 
resulting in reduced cellular fitness, RNR activity and dNTP levels, while deletion 
of Sml1 rescued those phenotypes (Andreson et al., 2010; Georgieva et al., 2000). 
In order to study the consequences of Rrm1WG on mammalian health, we aimed to 
generate mice carrying the Rrm1WG mutation in homozygosity. However, when 
intercrossing heterozygous Rrm1+/WG mice we observed that the Rrm1WG/WG point 
mutation led to homozygous lethality. No homozygous pups were born, nor were 
we able to detect homozygous mutant embryos at earlier developmental stages, 
demonstrating that Rrm1WG/WG causes early embryonic lethality in mice (Figure 
23).  
 
Figure 23: Rrm1WG/WG is homozygous lethal. (A) Table showing the observed genotypes 
of 3 week old pups, 13.5 dpc or 3.5 dpc embryos, obtained from crosses of Rrm1+/WG. (B) 
Genotyping PCR illustrating the two Rrm1 genotypes obtained. 
In mammals, the RRM1 subunit is believed to be present in excess while the RRM2 
subunit is rate limiting for enzyme activity (Engstrom et al., 1985). Hence, we 
explored whether the lethality of Rrm1WG/WG mice could be rescued by increased 
levels of RRM2. To this end, we crossed Rrm1+/WG heterozygous animals with the 
Rrm2Tg strain. However, increased RRM2 levels did not rescue homozygous 
lethality of the WG mutation as we failed to detect animals homozygous for 
Rrm1WG even in a genetic background of Rrm2Tg (Table 2). Collectively, these 
results reveal that the W684G mutation is essential for mammalian viability, in a 
way that cannot be rescued by an additional supply of RRM2. 
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4.3 Rrm1+/WG mice are phenotypically normal  
The early homozygous lethality of the RRM1-WG point mutation indicated that 
RNR function was severely compromised in Rrm1WG/WG mice, what prevented 
further characterization of the physiological consequences of Rrm1WG in mammals. 
Observing such a drastic effect of Rrm1WG/WG on the murine health, we analyzed the 
physiological consequences in mice carrying the Rrm1WG point mutation in 
heterozygosity. In contrast to Rrm1WG/WG, Rrm1+/WG mice were fertile, born at 
mendelian ratios and showed no obvious phenotype (Figure 23 and 24). The size 
and body weight of Rrm1+/WG mice were normal, indicating that the animals did not 
suffer from an overall deficiency in growth or proliferation rate (Figure 24).  
 
Figure 24:  Rrm1+/WG mice are phenotypically normal. A) Representative picture of 4 month old 
wt and Rrm1+/WG littermates. (B) Weight distribution of 2 month old wt and Rrm1+/WG mice.  
To determine if the essential nature of the Rrm1-WG mutation was due to an effect 
on protein levels, we first verified whether Rrm1+/WG cells presented normal 
expression of the mutant allele. Indeed, RT-PCR followed by sequencing revealed 
equivalent expression of the mutant and wt mRNAs in Rrm1+/WG cells (Figure 
Table 2: Supraphysiological levels of  
RRM2 do not rescue Rrm1WG/WG lethality. 
Table showing the observed genotypes of 3 
week old pups, obtained from intercrossing 
Rrm1+/WG Rrm2Tg animals. 
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25A,B). Western blotting also failed to show any noticeable differences in RRM1 
protein levels between wt and heterozygous cells (Figure 25C). Hence, wt and 
RRM1-WG versions of RRM1 coexist at similar levels in Rrm1+/WG cells. 
 
Figure 25: Rrm1-WG is normally expressed and Rrm1+/WG cells exhibit normal RRM1 protein 
levels.  (A) Real-time PCR (RT-PCR) analysis of Rrm1 expression levels in wt or Rrm1+/WG MEF. 
Results are representative of three independent experiments performed in triplicate. (B) Sequence 
chromatograms showing the mutations (TGG → GGC) generated in Rrm1-WG mice. The arrows 
indicate the positions of the mutations. (C) RRM1 Western blot analysis of B lymphocytes, testis and 
thymus from wt and Rrm1+/WG mice. Beta Actin was used as a loading control. 
4.4 RRM1-WG overexpression does not induce RS 
To overcome the limitations imposed by the lethality of the mutation in mice and 
further explore the consequences of RRM1-WG expression in mammals, we 
generated constructs comprising human RRM1 or RRM1-WG with a C-terminal 
Strep-tag that were stably expressed in the doxycycline-inducible FlpIn T-REx 293 
cell line (see Figure 13). The RRM1-(WG-)-Strep constructs were then used to 
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generate a doxycycline-inducible FlpIn T-Rex 293 cell line. First, we observed that 
the subcellular distribution and stability of RRM1-WG were comparable to those of 
wt RRM1 (Figure 26A).  
 
Figure 26: RRM1-WG exhibits normal cellular distribution and protein stability. (A) WB 
analysis of cytoplasmic, nuclear soluble and nuclear pellet fractions of FlpIn T-REx 293 cells 
overexpressing RRM1-Strep or RRM1-WG-Strep. Tubulin and H2A were used as controls for 
cytosolic and chromatin fractions respectively. (B) WB analysis of FlpIn T-REx 293 cells 
overexpressing RRM1-Strep or RRM1-WG-Strep after incubation with 25 µg/ml cycloheximide for 
the indicated time points. p21 was used as control for protein degradation. 
Moreover, and in agreement with the absence of obvious phenotypes on Rrm1+/WG 
mice, overexpression of RRM1-WG did not affect cell cycle progression nor had it 
any obvious impact on RNR activity as measured by HU-induced H2AX 
phosphorylation (Figure 27). Altogether, these results indicate that lethality of 
Rrm1WG/WG mice is not linked to lower levels, altered distribution or intrinsic 
toxicity of the RRM1-WG protein. 
 
 
 
Cytosol   Nucleus  Chromatin 
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Figure 27: Overexpression of RRM1-WG does not affect the cell cycle or RS. (A) WB and (B) 
cell cycle-analysis of Flp-In T-REx 293 cells expressing RRM1-Strep or RRM1-WG-Strep after 24 
(and 48) hours of doxycycline (Dox) induction. (C) HTM-mediated quantification of γH2AX 
intensities in Flp-In 293 T-REx cells expressing empty Strep vector (Control), RRM1-Strep or 
RRM1-WG-Strep treated with 0,5 mM HU for 4 hours. Data are representative of three independent 
analyses. A.U.= Arbitrary Units. 
4.5 Rrm1WG heterozygosity does not impact the response to DNA damage 
in cells and mice 
We first obtained MEFs from Rrm1+/WG mice and wt littermates both of which 
exhibited normal growth (Figure 28). 
 
Figure 28: Rrm1+/WG MEF proliferate 
normally. Growth curve of pairs of three 
Rrm1+/+ and Rrm1+/WG MEF lines derived from 
littermates. Data are representative of two 
independent analyses.  
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Despite the overall normal appearance of Rrm1+/WG mice, we explored whether the 
presence of the mutation might be more relevant in conditions that demand an 
extra supply of dNTPs, such as during DNA repair. To investigate whether RNR 
function was even slightly compromised in Rrm1+/WG, we exposed Rrm1+/+ and 
Rrm1+/WG MEFs to HU and compared the levels of γH2AX. HTM analyses revealed 
that HU-induced γH2AX levels were not altered on Rrm1+/WG MEFs when compared 
to those observed on littermate MEFs (Figure 29).   
 
Figure 29: MEF from Rrm1+/WG exhibit a normal RS-response. HTM-mediated quantification of 
γH2AX intensities in wt and Rrm1+/WG MEF treated with 0,5mM HU for 4 hours. Data are 
representative of three independent analyses. A.U.= Arbitrary Units 
Given that MEFs are a slow proliferating cell type, they are not particularly prone 
to RS. In contrast, lymphocytes undergo rapid proliferation cycles and therefore 
might have a more important demand of nucleotides. We purified B-cells from 
Rrm1+/WG and Rrm1+/+ mice and challenged them with HU or ionizing radiation 
(IR). Consistent with data from MEFs, phosphorylation of CHK1 and RPA were not 
affected in Rrm1+/WG B-cells (Figure 30). 
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Figure 30: Lymphocytes isolated from Rrm1+/WG exhibit a normal induction of the RS-
response. RRM1, phospho CHK1, CHK1, phospho RPA, and RPA Western blot in wt and Rrm1+/WG  
littermate B-cells, either untreated (Control) or upon treatment with 2mM HU for 3 hours or 10Gy 
IR. Data are representative of two independent analyses. -actin was used as a loading control. 
While we failed to detect an increase in the sensitivity towards RS or DNA damage 
inducing agents in Rrm1+/WG cells in vitro, we speculated that Rrm1+/WG animals 
could show more phenotypes when exposed to RS inducing conditions. Given that 
the hematopoietic stem cell (HSC) compartment is particularly sensitive to RS and 
DNA damage (Flach et al., 2014; Murga et al., 2009; Rossi et al., 2007) we evaluated 
the behavior of Rrm1+/WG HSC in vivo. To this end, we tested how wt and Rrm1+/WG 
HSC repopulate the bone marrow of mice exposed to a sub-lethal dose of IR. In 
agreement with in vitro data, hematopoietic recovery of Rrm1+/WG and Rrm1+/+ 
mice showed no significant differences (Figure 31). Collectively, the results above 
show that the expression of RRM1-WG to around half of the total amount of RRM1 
does not have a detectable impact on mammalian cells, supporting the notion that 
RRM1 exists largely in excess and that RNR activity is mostly dependent on RRM2. 
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Figure 31: Rrm1+/WG mice show a normal IR recovery. Hematopoietic recovery after a sublethal 
dose of irradiation (6 Gray). Blood indices from Rrm1+/WG mice are compared with wt mice at 1-5 
weeks post irradiation. Values are means ± SD, n = 6.  
4.6 RRM1-WG does not form the RNR holocomplex       
Even if Rrm1+/WG mice and cells had no obvious phenotype, the lethality of the 
allele in homozygosis indicated that the mutant protein was not functional. In 
yeast, the Rnr1-WG mutant leads to constitutive binding of the RNR inhibitor Sml1 
to Rnr1. In theory, the binding of murine RRM1-WG to a yet-unidentified RNR 
inhibitor could also explain the lethality of Rrm1WG/WG mice. To search for proteins 
that more avidly bind to RRM1-WG than to wt RRM1, we purified Strep-tagged 
RRM1 proteins and, with the help of the Proteomics Unit of the CNIO, looked for 
interactors by MS. However, no proteins specifically enriched in the RRM1-WG 
pull-downs were identified. In contrast, we observed a major reduction in the 
number of RRM2 and RRM2B peptides identified in RRM1-WG pull-downs (Figure 
32A). WB analysis confirmed a very significant reduction of the levels of RRM2 and 
RRM2B in RRM1-WG pull-downs (Figure 32B). The impaired formation of the 
RNR complex explains both the lethality of Rrm1WG/WG mice and the absence of 
toxic effects of the mutant protein even when overexpressed.  
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Figure 32: RRM1-WG interferes with RNR heterocomplex formation. (A) Strep-IP from total 
cell lysate of Flp-In T-REx 293 cells overexpressing an empty control vector, RRM1-Strep or RRM1-
WG-Strep protein. (B) Protein spectrum matches (PSM) of RRM2 and RRM2B identified by mass 
spectrometry in the fraction containing purified RRM1 or RRM1-WG.  
4.7 RRM1-WG binds RRM2(B) in vitro  
While the loss of RNR complex formation could explain the lethality observed in 
Rrm1WG/WG mice, this finding stands in contrast to the impact of the mutation in 
S.cerevisiae. Whereas the rnr1-WG mutation caused increased Rnr1-Sml1 binding, 
the formation of Rnr1-Rnr2 complexes was not compromised. Moreover, deletion 
of Sml1 rescued the Rnr1-WG phenotypes (Andreson et al., 2010). Interestingly, 
Chabes and colleagues reported that recombinant yeast Sml1 competes with RRM2 
binding to human RRM1, disrupting RNR complexes (Chabes et al., 1999). Hence, 
our observations of lower levels of RRM2 in RRM1-WG-Strep pull-downs could be 
explained in two different ways. The W684G mutation could directly impair the 
binding of murine RRM1 to RRM2. Alternatively, the mutation could increase the 
binding of RRM1 to another protein, precluding the RRM1-RRM2 interaction. In 
order to distinguish between those two possibilities, we analyzed the in vitro 
capacity of RRM1-WG to form the RNR complex. We expressed and purified 
mutant and wt RRM1, as well as RRM2 and RRM2B proteins with an N-terminal 
His-tag from Escherichia coli. Additionally, RRM1 proteins were purified with an N-
terminal Strep-tag to allow for an independent purification (Figure 33 and 34).  
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Figure 33: Experimental procedure to test the RRM1-WG RNR complex formation in vitro. 
Human Rrm1(WG), Rrm2 and Rrm2B with an N-terminal His tag were expressed in E.coli cells and 
purified with Ni-NTA beads. Similarly, human Rrm1(WG) with an N-terminal Strep tag was 
expressed in E.coli and purified with Strep-tactin beads. Purified Strep-RRM1 or Strep-RRM1-WG 
protein was then incubated with His-RRM1(WG) or His-RRM2(B) and purified by Strep-IP.  
 
Figure 34: Coomassie staining of the purification of Strep-RRM1, Strep-RRM1-WG, His-RRM1, His-
RRM1-WG, His-RRM2 and His-RRM2B. The white arrow indicates the band representing the 
purified protein. 
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Using purified proteins, we first observed that RRM1-WG can bind to wt RRM1 and 
form the RRM1 homodimer (Figure 35).  
  
Next, we tested whether recombinant RRM1-WG was able to bind RRM2 or RRM2B 
in vitro. Indeed, recombinant RRM1-WG bound both RNR regulatory subunits as 
efficiently as wt RRM1 (Figure 36). Because RNR holocomplex formation can be 
affected by binding of its effector nucleotides (Ahmad and Dealwis, 2013), we also 
tested complex formation in the presence and absence of physiological levels of 
ATP. Again, we observed no effect of the WG mutation on the binding to RRM2(B) 
(data not shown). Thus, the introduction of the W684G point mutation in murine 
RRM1 does not intrinsically affect its binding to RRM2 or RRM2B. 
 
 
Figure 35: RRM1-WG forms the RRM1 
homodimer. Strep and His WB analysis of 
Strep IP after incubation of Strep-RRM1 or 
Strep-RRM1-WG with His-RRM1 or His-
RRM1-WG.  
 
Figure 36: RRM1-WG binds RRM2(B) 
in vitro. Coomassie staining of Strep-IP 
after in vitro incubation of Strep-RRM1 
or Strep-RRM1-WG with His-RRM2 or 
RRM2B. 
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4.8 RRM1-WG does not bind RRM2(B) in cells 
The observation that RRM1-WG was proficient in forming the RNR complex in vitro 
indicated that another factor could interfere with RRM1-WG binding to RRM2 in 
cellulo. This factor might be a protein modification (e.g. phosphorylation of RRM1 
or RRM2) or another feature of the cellular environment that was absent from our 
in vitro experimental setup. Additionally, and as suggested in yeast, it could also be 
that another protein competed with the small RNR subunits for binding to RRM1. 
To further search for factors that could bind preferentially to RRM1-WG, Strep-
RRM1 and Strep-RRM1-WG proteins were reversibly linked to Strep-tactin beads 
and used as baits for pull-downs. Once again, MS analysis did not reveal any 
preferential interactors of RRM1-WG. In contrast, and in agreement with our 
previous data, recombinant RRM1-WG failed to pull-down RRM2 and RRM2B as 
efficiently as wt RRM1 (Figure 37). In summary, whereas RRM1-WG can bind to 
RRM2(B) in vitro it fails to form a RNR complex in vivo, which explains the lethality 
of Rrm1WG/WG mice. 
 
Figure 37: RRM1-WG fails to bind RRM2(B) in cellular extracts.  A) WB and B) Protein 
spectrum matches (PSM) of RRM2 and RRM2B protein identified by mass spectrometry in the 
fractions incubated with recombinant Strep-RRM1 or Strep-RRM1-WG protein reversibly linked to 
Strep-tactin beads. 
Collectively, our results demonstrate that the Rrm1-WG mutation also 
compromises RNR function in mammals, but through a different mechanism to 
what has been described for yeast. In mice, the RRM1-WG mutant protein fails to 
interact with RRM2(B) leading to early embryonic lethality. Whereas RRM1-WG 
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can bind to RRM2 using recombinant proteins, it does not in cells, in a way that 
could be consistent with the presence of a yet to be identified factor that competes 
with the RRM1-RRM2 binding. In contrast to the lethal effect of the Rrm1WG 
mutation in homozygosity, heterozygous mutant mice have no phenotype, 
supporting the idea that protein levels of RRM1 are not limiting for RNR function. 
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DISCUSSION 
The balanced regulation of dNTP levels is crucial to sustain proliferation while 
preventing mutagenesis. Previous work in model organisms suggests that ATR, the 
main checkoint kinase, safeguards genomic integrity by directly stimulating dNTP 
production upon demand and it has been speculated that it regulates the dNTP 
pool. In fact, yeast ATR ortholog Mec1 acts as a critical regulator of the nucleotide 
pool by activating RNR. In mammals, a relationship between nucleotide supply and 
oncogene-induced RS has recently been established (Bester et al., 2011), together 
with a connection between ATR and RNR to provide dNTPs during DNA repair 
(D'Angiolella et al., 2012). However, a direct connection between ATR signaling 
and RNR activity in the context of normal and aberrant DNA replication in 
mammals had not been explored in depth. In this work, we tried to identify new 
regulators of RNR activity, aimed to explore whether the ATR-dependent 
regulation of the RNR is conserved in mammals and how this regulation is 
established.  
1 ATR-dependent transcriptional regulation of the RNR is 
conserved in mammals 
Several lines of evidence support a critical function of ATR in regulating the RNR in 
mammals. Best defined is the role of ATR in the regulation of transcription of the 
RNR subunits, although conflicting data exist (see Introduction 2.2.2). Here, we 
observed that ATR not only induces the expression of Rrm2, but also increases the 
transcription of Rrm1. Importantly, artificially induced ATR signaling, in the 
absence of actual DNA damage, was sufficient to stimulate RNR transcription 
excluding the possibility that our results were biased by ATM signaling (Eaton et 
al., 2007). Interestingly, Rrm2b expression is not downregulated but rather 
overexpressed in response to CHK1 inhibitors, which could be explained by the 
fact that Rrm2b is a p53 target and CHK1 inhibition generates DNA breakages. Our 
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results support a conservation of the Mec1(ATR)-Rad53(CHK1)-dependent control 
of the expression of RNR genes in mammals. However, it remains unclear whether 
CHK1 induces Rrm1 transcription directly or via downstream mediators. In yeast, 
Mec1-Rad53 signaling in response to replication blocks is mediated via Dun1 and 
the transcriptional repressor of rnr2/rnr4/rnr3, Crt1.  The mammalian ortholog of 
Crt1 is RFX1, which regulates Rrm2 expression in response to ATR signaling 
through a conserved mechanism (Lubelsky et al., 2005). Although RFX1 contains a 
consensus CHK1 phosphorylation site (O'Neill et al., 2002), it has not been 
determined whether RFX1 acts downstream of CHK1 or is being directly 
phosphorylated by ATR (Lubelsky et al., 2005).  It has also been proposed that 
Rrm2 is controlled via ATR/ATM-CHK1-E2F1 during S-phase (DeGregori et al., 
1995) and in response to DNA damage (Zhang et al., 2009). Whether RFX1 or E2F1 
also mediate the ATR-CHK1-dependent regulation of Rrm1 expression remains to 
be adressed (Figure 38). 
 
 
                        
 
Figure 38: ATR-dependent transcriptional regulation of 
the canonical RNR subunits is conserved in mammals. 
ATR-CHK1 signaling induces E2F1, which in turn induces 
Rrm2. Rrm2 expression is also induced in response to ATR-
dependent phosphorylation of its inhibitor RFX1. Whether 
ATR-CHK1-dependent Rrm1 expression is mediated via 
RFX1, E2F1 or another mechanism is currently not known.  
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2 Is there a role for nuclear RNR?  
In yeast, Mec1 regulates RNR at different levels, from its subcellular localization 
and activity to its transcription. Although traditionally dNTP synthesis is believed 
to be a cytosolic process, it has been a matter of speculation whether part of the 
nucleotide metabolism is conducted within the nucleus. Although all mammalian 
RNR subunits are mainly cytosolic, the need for compartmentalization of 
nucleotide metabolism to the RF has been proposed based on the following 
observations: 1) intracellular nucleotide concentrations are lower than necessary 
for replication dynamics (Mathews, 1985; Warner, 1973); 2) in contrast to yeast, 
overall dNTP pools are almost unchanged after DNA damage in mammals 
(Hakansson et al., 2006b); 3) nucleotides are highly vulnerable to alterations by 
ROS (Mathews, 2006) and compartmentalization would provide fresh dNTPs for 
replication; 4) the RNR was found to travel with the RF in E.coli  (Sanchez-Romero 
et al., 2010). The speculations about a role for nuclear RNR were recently fueled by 
a number of publications reporting nuclear targeting of RNR to sites of DSB 
(D'Angiolella et al., 2012; Hu et al., 2012; Niida et al., 2010a; Zhang et al., 2009). In 
contrast to DNA repair, and through several independent approaches such as 
isolation of proteins on nascent DNA (iPOND), biochemical fractionation or 
immunofluorescence, we have failed to detect an increase in nuclear RNR in 
replicating chromatin or even at the RF (data not shown). Those results suggest 
that the nuclear translocation of the RNR might be specific for DNA break repair 
and not required during DNA replication or RS. Although it is possible that the DNA 
damage-induced translocation of the RNR has non-nucleotide reduction related 
function, this explanation seems unlikely for various reasons. On one hand, the 
recruitment of the RNR seems to be critical only in the context of low dNTP levels 
during G0/G1. On the other hand, its reductase activity is essential for efficient 
DNA repair (Hakansson et al., 2006b; Niida et al., 2010a). Thus, the need for a 
localized nucleotide production at sites of DNA repair might stem from the low 
overall dNTP levels in resting cells. The dNTP pool is increased 15-20 times during 
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S-phase, while DNA damage does not cause major nucleotide pool expansions in 
mammalian cells (Hakansson et al., 2006b). In this context cells may require a 
specific mechanism to provide dNTPs for DNA repair while during DNA replication, 
elevated dNTP levels in the nucleus are sufficient to duplicate the DNA. In support 
of this hypothesis, RRM2B, the subunit involved in DSB repair, shows a more 
pronounced nuclear localization compared to RRM2, the subunit providing dNTPs 
for DNA replication (Figure 38).  
 
Figure 38: Cellular distribution of RRM2 and RRM2B in U2OS cells. 
Besides RRM2B, immunohistochemistry data from Rrm2Tg mice show a mainly 
cytoplasmic distribution of RRM2 in all tissues except for testis, where RRM2 
shows a clear nuclear localization (Figure 39). Given that the spermatocytes are 
constitutively exposed to high amounts of DNA breakage (Sasaki and Matsui, 
2008), these results suggest that the nuclear localization of RNR might be 
particularly relevant for cells undergoing active DNA repair. 
 
Figure 39: RRM2 levels in tissues of wt and Rrm2Tg mice. RRM2 immunohistochemistry of wt 
and Rrm2Tg spleen and testis. Note that whereas RRM2 is cytoplasmic in spleen (and other organs), 
it is nuclear in testis, in agreement with the increase of nuclear RRM2 levels that has been observed 
in response to DNA damage (Lopez-Contreras et al., 2015).  
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Alternatively, the failure to detect the RNR at RFs might be due to technical 
limitations. In this line, it would be interesting to study whether cells expressing 
exclusively cytoplasmic RNR subunits in a RNR-deficient background proliferate 
normally under unchallenged conditions. If so, a role for nuclear RNR during 
normal replication would be unlikely. In addition, this approach would allow to 
test whether the potential nuclear localization of the distinct RNR subunits might 
be independent of the complex and unrelated to dNTP production as previously 
proposed (Gautam et al., 2003). 
Finally and besides the RNR, dNTP synthesis requires multiple enzymes and it is 
possible that other steps of the dNTP production process act locally at the 
replisome. Interestingly, the de novo thymidylate synthesis pathway forms a 
multienzyme complex that has been detected at RFs (Hu et al., 2012). Additionally, 
the nucleotide diphosphate kinase NME1, essential for conversion of dNDPs 
produced by the RNR into nucleotides, has been found to translocate to the nucleus 
in response to DNA damage (Kaetzel et al., 2006). Furthermore, NME1 and its 
homolog NME2 have recently been shown to localize to the RF (Aranda et al., 
2014). These results suggest that while the RNR might not be at RFs, the final step 
of dNTP production in mammals might happen preferentially around sites of DNA 
replication. 
3 Exploring new interactors of the RNR 
Besides our interest in ATR biology, we here sought to identify new ways to 
regulate the mammalian RNR. Through multiple approaches, we provide a 
comprehensive analysis of proteins potentially binding to the RNR complex. 
However, none of them could be confirmed as a true interactor, suggesting that the 
mammalian RNR might not be regulated via other protein inhibitors/activators. 
Alternatively, ATR may regulate RNR by other means, most prominently through 
post-translational modifications. In fact, ATM- and ATR-dependent 
phosphorylations of RRM2B and RRM2 have been implicated in their stabilization 
in response to DNA damage (Chang et al., 2008; D'Angiolella et al., 2012). However, 
Discussion 
[98] 
 
whether and how this signaling plays a role during replication and RS remains to 
be explored. In addition, and although we did not identify any new protein 
interactors, we cannot exclude that the RNR complex interacts with another 
protein under certain conditions (see below IRBIT). Taken together, our results 
indicate that the RNR is a rather stable heterocomplex composed of the RRM1, 
RRM2 and RRM2B subunits and it does not seem to be regulated by another 
protein at stoichiometric levels. 
4 KPNB1 suppresses RS 
A recent paper by Mercedes Dosil reported that the ribosome biogenesis factor 
Rrp12 is involved in karyopherin (Kap121)-dependent nuclear import of the small 
RNR subunits Rnr2 and Rnr4 (Dosil, 2011). Defective function of Rrp12/Kap121-
dependent nuclear import of Rnr2/Rnr4 led to aberrant dNTP levels, defects in the 
DNA damage response and S-phase progression. Here, we identify the mammalian 
karyopherin KPNB1 as a new regulator of the RNR. In agreement with data from 
yeast, depletion of KPNB1 slows down proliferation and increases RS. In yeast, the 
defects in karyopherin mutants are rescued by overexpression of Rrp12. In 
contrast, we find that depletion of human RRP12 does not induce RS and its 
overexpression does not rescue RS induced by KPNB1-depletion (data not shown). 
Of note, although we failed to detect any effect of KPNB1 depletion on the 
distribution of the RNR subunits, we observed an overall reduction of RRM2 and 
RRM2B levels after downregulation of KPNB1. Whether this is a direct 
consequence or a secondary effect caused by a perturbation of the cell cycle 
remains to be explored. 
In this work we establish a new function for KPNB1 as a suppressor of RS induced 
by reduced dNTP levels, opening up the question on how KPNB1 regulates RS 
levels. We propose two potential mechanisms. First, KPNB1 could directly import 
RSR proteins into the nucleus, thereby affecting RSR function. Second, KPNB1 
could indirectly contribute to the regulation of the dNTP pool through the 
modulation of the transport of a different substrate. Indeed, KPNB1 can regulate 
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dNTP levels by mediating the nuclear import of the dNTP nuclease sterile alpha 
motif (SAM) and HD domain containing 1 (SAMHD1), a step essential for its 
degradation. Reduced KPNB1 levels lead to a cytosolic accumulation of active 
SAMHD1 which negatively affects dNTP pool levels (Schaller et al., 2014). Whether 
this mechanism accounts for the KPNB1-dependent regulation of RS remains to be 
further investigated (Figure 40).  
 
Figure 40: Model for KPNB1-dependent regulation of cellular RS levels. KPNB1 acts on the 
dNTP pool by mediating nuclear import of SAMHD1 (Schaller et al., 2014). In addition, KPNB1 could 
regulate RS levels through the nuclear import of an unknown protein of the RSR. 
Cancer cells frequently suffer from high levels of oncogene-induced RS caused by 
forced and untimely hyper-replication. In parallel, RS-promoting oncogenes 
frequently upregulate proteins of the RSR and dNTP production pathways to cope 
with these increased levels of RS (Aye et al., 2015; Hoglund et al., 2011; Schulze et 
al., 2014; Verlinden et al., 2007). This upregulation is often achieved via 
deregulation of the RB/E2F pathway, a key cell cycle regulator disrupted in almost 
all human cancers (Reviewed in (Nevins, 2001)). Interestingly, KPNB1 is an E2F 
target and frequently overexpressed in cancer cells (van der Watt et al., 2011) and 
tumor cells seem to be particularly dependent on high KPNB1 levels with its 
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inhibition leading to cell death via apoptosis (van der Watt et al., 2009). Previous 
studies in our lab revealed that overexpression of the RSR protein and E2F target 
CHK1 promotes oncogene-induced transformation protecting cancer cells from RS 
(Lopez-Contreras et al., 2012). Therefore, we propose that KPNB1 overexpression 
might promote malignant transformation by limiting RS in cancer. In agreement 
with this hypothesis, KPNB1 was recently identified as a potential anticancer 
target (van der Watt et al., 2013). Our work suggests that strategies targeting 
KPNB1 in combination with other RS-inducing drugs such as ATRi might be 
specifically toxic for tumor cells and could be explored as a therapy for certain 
types of cancer. 
5 An extra supply of dNTPs reduces the pathological consequences 
of RS 
In this work, we demonstrate that addition of nucleosides to cell culture media 
alleviates RS and growth defects caused by deficient ATR activity. Our results 
complement a number of recent studies reporting that an exogenous supply of 
nucleosides reduces the pathological consequences of RS such as growth defects, 
DNA damage and genomic rearrangements in vitro. Bester and colleagues showed 
in 2011 that the DNA damage caused by oncogene-induced RS could be suppressed 
by an exogenous supply of nucleosides (Bester et al., 2011). In agreement with this, 
MEFs transformed by Ras/E1A oncogenes exhibit lower RS and transform more 
efficiently when nucleosides are added to the medium, suggesting that an 
increased nucleotide supply helps to promote survival during transformation (our 
own observations). In addition, reduced RS and increased survival during 
Ras/E1A-induced transformation was also observed in cells carrying an extra 
allele of Chk1 (Lopez-Contreras et al., 2012), supporting the idea that ATR/CHK1 
signaling and nucleoside supplementation have similar consequences. Analogous 
to oncogene-induced RS, we recently described reprogramming-induced RS as a 
source for genomic instability in induced pluripotent stem (iPS) cells (Ruiz, 2015). 
Addition of nucleosides during somatic cell reprogramming alleviates RS, as 
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observed after oncogene-induced transformation, which leads to reduced genomic 
rearrangements on the resultant iPS. Together, those results show that stimulation 
of dNTP production reduces the pathological consequences of RS in vitro and 
establish dNTPs scarcity as a key source for RS.  
The DNA damage and genomic instability derived from RS are known causes for 
cancer and aging in humans (Lecona and Fernandez-Capetillo, 2014). This opens 
up the question as to whether a stimulation of dNTP production can also lower the 
pathological consequences of RS in vivo. Regarding the role of increased dNTP 
supply during cancer development, the data is controversial and points towards a 
dose and stage specific effect. A previous report showed that widespread 
overexpression of the small RNR subunits potently and selectively induces Non 
small cell lung cancer (NSCLC) in transgenic mice and is mutagenic in cultured cells 
(Xu et al., 2008). In contrast, we did not observe enhanced tumor incidence in 
Rrm2Tg mice. One possible explanation for this discrepancy is that we expressed 
RRM2 under its endogenous promoter, avoiding ectopic overexpression in places 
where RRM2 is usually not expressed, such as the lung. To further clarify this issue 
and given the fact that RNR-induced lung neoplasms were associated with K-ras 
proto-oncogene mutations, we crossed Rrm2Tg mice with a genetic model of lung-
carcinogenesis induced by the K-Ras oncogene (Guerra et al., 2003). Again, we 
failed to detect a higher incidence of tumors in this model. We conclude that 
increased RNR activity in Rrm2Tg mice does not promote tumor formation. In 
contrast, increased RNR activity reduces RS and diminishes the severity of 
pathologies associated with ATR-Seckel, namely premature aging and death. 
Hence, reduced dNTP levels are a main cause for ATR deficient phenotypes in 
mammals and an increased supply of dNTPs can indeed reduce RS-derived 
pathologies in mice. Interestingly, folates, essential for de novo synthesis of 
thymidine and purines, are routinely used in the clinic for the prevention or 
treatment of a wide range of age-associated diseases, including cancer. Low folate 
levels seem to play an important role in ageing brain processes like Alzheimer's 
disease and vascular dementia (Reynolds, 2002) as well as during tumor 
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development (Kim, 1999), and higher intake of folates in the diet correlates with 
reduced risk for those diseases (Ericson et al., 2007; Mason, 2011). However, it 
remains unclear whether folate supplementation is only beneficial in the context of 
folate deficiency, which is particularly common among elderly people, and some 
concerns have been raised regarding an excess intake of folates (Kim, 2004). 
Nevertheless, the data from mice and human suggest that an enhancement of dNTP 
metabolism has beneficial effects over cancer development and other age-related 
diseases in mammals, as long as it stays below a certain threshold (Figure 41). In 
this context, it would be interesting to explore whether increased dNTP levels 
could also rescue other types of genomic instability diseases as has recently been 
described for yeast (Poli et al., 2012). The Rrm2Tg mouse provides a valuable model 
of enhanced RNR activity and could be used to further study the impact of 
increased RNR activity on other genomic instability driven diseases. In any case, 
the work presented here supports that evaluating whether and which types of 
medical conditions could benefit from increased dNTP levels demands further 
investigation. 
Figure 41: Increased levels of dNTPs help to reduce 
cancer and aging in mammals. Elevated dNTP levels due 
to a stimulation of dNTP synthesis lead to reduced RS, 
which results in reduced genomic instability affecting 
cancer and aging in vivo. 
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5.1 How does limited ATR activity relate to dNTP pools? 
An obvious remaining question of our work is, why are the dNTP pools decreased 
in ATR-Seckel mice? Is this directly caused by reduced RNR activity like in yeast 
mec1Δ mutants? What are the essential mechanisms linking ATR and RNR? On one 
hand, ATR can regulate the transcription of RRM2. Upon DNA damage, ATR has 
also been shown to limit the degradation of RRM2 (D'Angiolella et al., 2012). 
However, this mechanism has only been linked to DNA damage and limited to G2 
and cannot explain how ATR regulates RNR during replication and RS. Further, 
ATR deficiency leads to increased origin firing (Paulsen and Cimprich, 2007) and 
causes an exhaustion of the dNTP pool. Therefore, increased RNR activity might 
provide sufficient dNTPs under conditions of increased demand, such as when 
multiple origins are fired. Based on the homology to yeast, we think that yet 
another regulatory mechanism might exist, namely, the regulation of RNR activity 
by ATR. In this context, it would be highly valuable to develop a new method to 
directly measure local RNR activity. So far, RNR activity is evaluated by measuring 
dNTP levels, a technically complicated and rather imprecise method detecting 
whole cell nucleotide levels. The development of an alternative activity assay 
would allow to study the connection between ATR signaling and RNR activity and 
could further help in the search for factors that induce RNR activity. Then, 
strategies to increase the activity of RNR could be further explored for a potential 
therapeutic use in certain types of human diseases (see above). 
6 Limiting RNR function in vivo: the search for a mammalian Sml1 
We here show that the RRM1W684G point mutation compromises RRM1 function 
in mice, yet, the mechanism differs from that reported in yeast. In mice, the RRM1-
W684G mutation prevents the RRM1-RRM2(B) interaction and leads to early 
embryonic lethality. Interestingly, recombinant RRM1-WG interacts normally with 
RRM2(B) in vitro, which raises the question of why the RNR complex does not form 
in vivo with RRM1-WG. One option is that post-translational modifications that 
Discussion 
[104] 
 
occur in vivo are necessary to prevent the interaction. Alternatively, RRM1-WG 
could bind another protein in vivo blocking RRM1 binding to RRM2(B). In 
accordance with this hypothesis, studies with recombinant mammalian RNR 
suggest that binding of yeast Sml1 to RRM1 interferes with binding to RRM2 
(Chabes et al., 1999). Unfortunately, we have been unable to find a factor with 
increased affinity for RRM1-WG in mammalian cells. A third explanation for the 
loss of the RRM1-WG-RRM2(B) interaction relies on the suggested function of the 
sequence surrounding the point mutation. In yeast, this region mediates the 
interaction with the neighbouring Rnr1-CTD, an essential step required for 
complex regeneration (Zhang et al., 2007). Sml1 binds to this region and 
outcompetes Rnr1-CTD, preventing the regeneration of active RNR. Because the 
RRM1 sequence is highly conserved, it is also possible that the point mutation 
induces constitutive binding of the neighbouring Rnr1-CTD, impeding reactivation 
of the RNR and interfering with the binding to RRM2(B) (Figure 40). Regardless of 
the mechanism, the fact that the mutant protein fails to participate in RNR 
complexes explains the early embryonic lethality as well as the absence of toxic 
effects of RRM1-WG even when overexpressed. In conclusion, our study shows that 
the conserved RRM1-WG residue is essential for the formation of a functional RNR 
complex in mammals and that this step is essential for mammalian cellular 
viability. 
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Figure 40: Potential mechanisms interfering with RRM1-WG binding to RRM2(b) in vivo. (A) 
The formation of the RNR heterocomplex or RRM1 homodimer might be compromised by protein 
modifications (red star) e.g. on RRM2(b) or RRM1. (B) Alternatively, binding of an unknown 
protein to RRM1-WG might interfere with complex formation (green rectangle). (C) Irreversible 
interaction of RRM1-CTD to the neighbouring RRM1-WG could impede binding of the small 
subunits. 
In what regards to the identification of a mammalian Sml1, proteomic analyses 
failed to detect any protein that binds more avidly to RRM1 carrying the W684G 
mutation than to wt RRM1. A recent study proposed IRBIT as a mammalian 
ortholog for Sml1 that interacts with the RRM1-RRM2(B) complex (Arnaoutov and 
Dasso, 2014). In contrast, we did not detect any interaction between IRBIT and 
RRM1 or RRM1-WG, what might be explained by the fact that the IRBIT-RNR 
interaction seems to be limited to mitosis. To further clarify whether IRBIT might 
act as a mammalian ortholog of Sml1, we are currently crossing IRBIT knock out 
mice with ATR-Seckel mice. If IRBIT were to act homologous to Sml1, this cross 
should rescue the pathologies associated with ATR-deficiency, just as mec1Δ can be 
rescued by depleting Sml1 (Zhao et al., 1998). In addition, we are now conducting a 
genome wide screening for genes that, when knocked out, confer resistance to ATR 
inhibition. We hope that these experiments might shed further light on the 
essential functions of ATR in mammals. 
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6.1 Protein levels of RRM1 are not limiting in mammals 
In humans, the Rrm1 gene lies at 11p15.5, a tumor suppressor region (Pitterle et 
al., 1999) and RRM1 expression levels have been correlated with DNA repair 
capacity in response to certain chemotherapeutic drugs (Aye et al., 2015). 
Accordingly, the levels of RRM1 have been proposed to predict sensitivity to 
chemotherapy in pancreatic and non-small cell lung cancers, although conflicting 
data exist (Besse et al., 2013). Here we show that having one functional RRM1 is 
sufficient for an efficient RS response, normal mouse development and organ 
function, which argues against the view that RRM1 levels would be reliable 
predictors of response to treatment. So far, we failed to detect an increased tumor 
incidence in mice with reduced wt RRM1 levels further arguing against a major 
role for RRM1 heterozygosity in tumor suppression. Together, those results 
suggest that RRM1 exists in large excess in mammalian cells, and that RNR function 
mainly depends on the availability of RRM2. As a consequence, a reduction of 
RRM1 levels to as much as 50% would have negligible effects on RNR function. 
This finding has important implications for the clinic as it casts doubt on the utility 
of RRM1 levels as marker for resistance to treatment. In contrast, our data suggest 
that any changes in RRM1 levels, to be considered meaningful as guidance for 
treatment, should reduce RRM1 expression below 50%. 
In conclusion, we present the characterization of the first loss-of-function mouse 
model of the RNR, reveal a single amino acid change that is essential for life in 
mammals and show that RRM1 levels are not limiting for RNR function, which 
would mostly depend on the presence of RRM2. 
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CONCLUSIONS 
ATR and the RNR 
1. ATR activity stimulates the expression of RRM1 and RRM2. 
2. Nucleoside supplementation reduces the RS and growth deficiencies of 
ATR-Seckel cells. 
3. Increased RRM2 levels reduce the severity of the symptoms found on ATR-
Seckel mice and significantly extend their lifespan. 
 
New Interactors of the RNR 
4. KPNB1 (importin subunit beta-1), is identified as a putative new regulator 
of the mammalian RNR. 
5. KPNB1 overexpression reduces, and depletion augments, RS in human cells. 
6. Proteomic analyses on purified RNR complexes failed to identify any factor 
that interacts with the mammalian RNR at a ratio similar to RRM1, RRM2 or 
RRM2B. 
 
A new mouse model of RRM1 
7. A single aminoacid change in RRM1 is incompatible with life in mice. 
8. Rrm1WG heterozygosity does not affect the function of the RNR nor has a 
detectable impact in mice. 
9. Proteomic analyses failed to identify any factor that binds more avidly to 
RRM1-W684G than to wild type RRM1. 
10. Whereas recombinant RRM1-W684G interacts with RRM2 in vitro, it fails to 
do so in vivo, providing an explanation for the essential nature of the 
mutation. 
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11. The absence of phenotypes on Rrm1WG heterozygous mice indicates that 
RRM1 levels are largely in excess in mammalian cells. 
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CONCLUSIONES 
ATR y la RNR 
1. La actividad de ATR induce la expresión de RRM1 y RRM2. 
2. El suplemento con nucleósidos reduce el estrés replicativo y los defectos en 
el crecimiento de las células ATR-Seckel.   
3. Niveles elevados de RRM2 disminuyen la gravedad de los síntomas que se 
manifiestan en los ratones ATR-Seckel e incrementan significativamente su 
esperanza de vida.  
 
Nuevos interactores de la RNR 
4. La KPNB1 (subunidad beta-1 de la importina) es identificada como un 
presunto nuevo regulador de la RNR en mamíferos.  
5. La sobreexpresión de KPNB1 reduce, y su eliminación aumenta, el estrés 
replicativo en células humanas.  
6. El análisis proteómico de complejos purificados de RNR no logró identificar 
ningún factor que interaccione con la RNR de mamíferos en proporciones 
similares a las que presentan RRM1, RRM2 o RRM2B. 
 
Un nuevo modelo murino de RRM1 
7. El cambio de un solo aminoácido en RRM1 es incompatible con la vida en 
ratones.  
8. Rrm1WG en heterocigosis no afecta a la función de RNR ni tiene ningún 
impacto detectable en ratones.  
9. El análisis proteómico no permitió identificar ningún factor que se una con 
mayor afinidad a RRM1-W684G que a la forma silvestre de RRM1. 
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10. Mientras que la proteína recombinante RRM1-W684G interacciona con 
RRM2 in vitro, no es capaz de hacerlo in vivo, proporcionando así una 
explicación a la naturaleza esencial de la mutación.  
11. La ausencia de fenotipos en ratones heterocigotos para Rrm1WG indica que 
RRM1 se encuentra ampliamente en exceso en las células de mamíferos. 
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